T1	SectionAnnotate 3475 3492	Interval History:
T2	SectionAnnotate 4271 4289	Review of Systems:
T4	SectionSkip 5002 8502	Current Outpatient Medications   Medication Sig Dispense Refill    diphenoxylate-atropine (LOMOTIL) 2.5-0.025 mg tablet Take 1 tablet by mouth 4 (four) times daily as needed for Diarrhea 60 tablet 1    EYEBRIGHT ORAL Take by mouth.      gabapentin (NEURONTIN) 300 mg capsule Take 1 capsule (300 mg total) by mouth 3 (three) times daily. 90 capsule 5    glucosam/chond/collagen/hyalur (JOINT SUPPORT ORAL) Take by mouth.      Lactobacillus acidophilus (PROBIOTIC ORAL) Take by mouth.      loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    LORazepam (ATIVAN) 0.5 mg tablet Take 1 tablet (0.5 mg total) by mouth every 8 (eight) hours as needed (nausea) 30 tablet 3    multivitamin tablet Take 1 tablet by mouth daily.      
 ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. 30 tablet 5    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting) 30 tablet 5    acetaminophen (TYLENOL) 500 mg tablet Take 500 mg by mouth every 6 (six) hours as needed for Pain.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. (Patient not taking: Reported on 10/22/2019  ) 30 g 2    oxyCODONE (ROXICODONE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 10/01/2019  ) 20 tablet 0    potassium chloride (KLOR-CON 10) 10 mEq ER tablet Take 2 tablets (20 mEq total) by mouth daily 60 tablet 3     No current facility-administered medications for this visit.      Facility-Administered Medications Ordered in Other Visits   Medication Dose Route Frequency Provider Last Rate Last Dose    0.9 % sodium chloride infusion  10-30 mL/hr Intravenous Continuous ***** *****, MD        albuterol (PROVENTIL HFA;VENTOLIN HFA) 90 mcg/actuation inhaler 2 puff  2 puff Inhalation Once PRN ***** *****, MD        dextrose 5% infusion  10-30 mL/hr Intravenous Continuous ***** *****, MD 30 mL/hr at 01/21/20 1220 30 mL/hr at 01/21/20 1220    diphenhydrAMINE (BENADRYL) injection 50 mg  50 mg Intravenous Once PRN ***** *****, MD        EPINEPHrine (EPIPEN) injection 0.3 mg  0.3 mg Intramuscular Once PRN ***** *****, MD        fluorouraciL (ADRUCIL) 4,032 mg in sodium chloride 0.9 % 92 mL chemo infusion - for home use  2,400 mg/m2 (Treatment Plan Recorded) Intravenous Once Q46H (Pump) ***** ***** *****, *****        heparin flush 100 unit/mL injection syringe 300 Units  300 Units Intravenous PRN ***** *****, MD        heparin flush 100 
 unit/mL injection syringe 500 Units  500 Units Intravenous PRN ***** ***** *****, *****   500 Units at 01/21/20 0941    heparin flush 100 unit/mL injection syringe 500 Units  500 Units Intravenous PRN ***** *****, MD        hydrocortisone sodium succinate (SOLU-CORTEF) 100 mg/2 mL injection 100 mg  100 mg Intravenous Once PRN ***** *****, MD        leucovorin (WELLCOVORIN) 672 mg in dextrose 5% 308 mL infusion  400 mg/m2 (Treatment Plan Recorded) Intravenous Once ***** ***** *****, *****        LORazepam (ATIVAN) tablet 1 mg  1 mg Oral Once PRN ***** *****, MD        oxaliplatin (ELOXATIN) 142.8 mg in dextrose 5% 579 mL chemo infusion  85 mg/m2 (Treatment Plan Recorded) Intravenous Once ***** ***** *****, *****
T5	SectionSkip 8513 8523	Allergies:
T6	SectionSkip 8689 9612	PHYSICAL EXAM  Vitals:  Vitals    01/21/20 1106   BP: 137/70   Pulse: 94   Resp: 18   Temp: 37.1 C (98.8 F)   SpO2: 97%   Weight: 64 kg (141 lb)   Height: 159 cm (5' 2.6")   PainSc:  0         Constitutional: Normal appearance. No acute distress. Not ill-appearing. Not diaphoretic.  Head: Normocephalic, atraumatic. External ears normal. Nose normal.    Eyes: Extraocular movements intact. Conjunctivae normal. No eye discharge. No scleral icterus.  Neck: Normal range of motion.   Pulmonary/Chest: Normal effort. No respiratory distress. No cough.  GI: No abdominal distention.   Musculoskeletal: No apparent edema.   Skin: Not jaundiced. Not pale. No visible erythema. No visible rash.  Neurological: Alert and oriented to person, place and time. Able to stand from sitting and walk.   Psychiatric: Normal mood and affect. Behavior is normal. Judgment and thought content normal.   ECOG Performance Status: 1 on 01/21/20
T7	SectionSkip 9616 9760	Laboratory Results-reviewed with patient today:    Key elements of latest CBC values... Please see Chart 
 Review for additional result details.
T8	SectionSkip 9762 10026	Lab Results   Component Value Date    WBC Count 30.6 (H) 01/21/2020    Hemoglobin 8.7 (L) 01/21/2020    Hematocrit 27.1 (L) 01/21/2020    MCV 99 01/21/2020    Platelet Count 192 01/21/2020     Neutrophil Absolute Count (x10E9/L)   Date Value   01/21/2020 24.06 (H)
T9	SectionSkip 10033 10766	Lab Results   Component Value Date    Albumin, Serum / Plasma 4.4 09/24/2019    Alkaline Phosphatase 204 (H) 01/21/2020    Alanine transaminase 22 01/21/2020    Aspartate transaminase 39 01/21/2020    Bilirubin, Total 0.4 01/21/2020    Urea Nitrogen, Serum / Plasma 13 01/21/2020    Calcium, total, Serum / Plasma 8.9 01/21/2020    Chloride, Serum / Plasma 104 01/21/2020    Carbon Dioxide, Total 25 01/21/2020    Anion Gap 12 01/21/2020    Creatinine 1.09 (H) 01/21/2020    eGFR if non-African American 50 01/21/2020    eGFR if African Amer 58 01/21/2020    Glucose, non-fasting 107 01/21/2020    Potassium, Serum / Plasma 2.9 (LL) 01/21/2020    Sodium, Serum / Plasma 141 01/21/2020    Protein, Total, Serum / Plasma 7.7 09/24/2019
T10	SectionSkip 10773 10955	Lab Results   Component Value Date    Int'l Normaliz Ratio 1.2 10/15/2019    PT 14.4 10/15/2019       No results found for: HCV, HCVEXL, HCVEXQ, HCVG, HCVRNAQUAL, HCVRNAQUANT, HCVEXT
T11	SectionSkip 10957 11737	Lab Results   Component Value Date    HBCAB NEG 10/15/2019    HBSAG NEG 10/15/2019     Cancer Antigen 19-9   Date Value Ref Range Status   01/07/2020 8,274 (H) <38 U/mL Final     Comment:     Performed using the ***** Architect Chemiluminescent Microparticle Immunoassay (*****).     Carcinoembryonic Antigen   Date Value Ref Range Status   12/10/2019 4.2 <5.1 ug/L Final     Comment:     Performed using the ***** Architect Chemiluminescent Microparticle Immunoassay (*****).         Imaging Results:    I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:  Ct Abdomen /pelvis With Contrast    Result Date: 
 12/10/2019  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** 8:35 AM
T12	SectionSkip 12124 14075	FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Liver:  Diffuse hepatic steatosis. Heterogeneous and diminished enhancement. Mild intrahepatic biliary ductal dilatation. Gallbladder: Unremarkable Spleen:  Unremarkable Pancreas:  4.4 x 3.5 cm mass in pancreatic body (series 5, image 48), with upstream pancreatic ductal dilatation and parenchymal atrophy, similar to prior study from 09/24/2019. Adrenal Glands:  Unremarkable Kidneys:  Unremarkable GI Tract: Small hiatal hernia. Diffuse wall edema involving the ascending and transverse colon. No obstruction. Vasculature:  Encasement and obstruction of the portal confluence by the pancreatic mass, with further attenuation of right and left portal veins. Encasement of celiac axis and superior mesenteric artery, with severe stenosis of hepatic artery, splenic artery, as well as superior mesenteric artery. Lymphadenopathy: Several periportal/peripancreatic lymph nodes measuring up to 1 cm, grossly similar to prior study. Peritoneum: Mild edema and trace ascites in upper abdomen. Bladder: Unremarkable Reproductive organs: Unremarkable Bones:  Multilevel degenerative changes in thoracic and lumbar spine, with grade 1 anterolisthesis of L3 on L4 and L4 on L5. Extraperitoneal soft tissues: Substantial interval weight loss. Lines/drains/medical devices: None RADIATION DOSE INDICATORS: Exposure Events: 4 , CTDIvol Min: 12 mGy, CTDIvol Max: 13.4 mGy, 
 DLP: 1012.8 mGy.cm. The following accession numbers are related to this dose report *****,*****     1. Pancreatic mass as detailed above, with encasement and severe narrowing of celiac and superior mesenteric arteries. 2. Ascending and transverse colitis. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Ct Chest With Contrast    Result Date: 12/10/2019  CT CHEST WITH CONTRAST
T13	SectionSkip 14557 15737	FINDINGS: LUNGS: Unchanged right upper lobe mixed solid groundglass nodule measuring 1.0 x 0.5 cm (series 14 image 56). Unchanged nodular scar or atelectasis adjacent to the osteophyte in the medial right lower lobe. No new nodules. PLEURA: The pleura is normal. MEDIASTINUM: No intrathoracic lymphadenopathy by CT size criteria. Heterogeneous appearance of the right thyroid gland is unchanged. HEART/GREAT VESSELS: New right chest port with tip in the lower right atrium. Unchanged mild flattening of the ventricular septum which may be due to increased right heart pressures. BONES/SOFT TISSUES: No suspicious bone or soft tissue lesions in the chest. VISIBLE ABDOMEN: Please refer to CT of the abdomen and pelvis reported separately for intra-abdominal findings.     1. No significant interval change in right upper lobe mixed solid and groundglass nodule measuring 1.0 x 0.5 cm. This may reflect scarring, primary lung neoplasm (specifically pulmonary adenocarcinoma), or metastatic disease. 
 Continued surveillance is recommended. Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging        Relevant New
T14	SectionSkip 15738 15897	Pathology:  09/09/19 FNA Pancreatic Tail Mass  A: Pancreas tail mass, Endoscopic ultrasound-guided fine needle  aspiration biopsy: Adenocarcinoma; see comment.
T15	SectionAnnotate 16252 16283	Impression and Recommendations:
T16	PROBLEM 140 178	her locally advanced pancreatic cancer
T17	PROBLEM 239 258	decreased PO intake
T18	PROBLEM 260 291	epigastric abdominal discomfort
T19	PROBLEM 293 308	new dx diabetes
T20	TEST 314 317	A1C
T21	TEST 323 329	Workup
T22	Radiology 339 360	a CT AP with contrast
T23	PROBLEM 374 419	3.1x2.1cm ill defined mass in pancreatic body
T24	RadPathResult 425 445	upstream PD dilation
T25	RadPathResult 447 459	tail atrophy
T26	PROBLEM 461 523	encasement of celiac axis, CHA, proximal splenic        artery
T27	PROBLEM 588 607	moderately narrowed
T28	PROBLEM 610 657	Mildly enlarged gastrohepatic and periportal LN
T29	RadPathResult 671 688	hepatic steatosis
T30	ProcedureName 756 759	EUS
T31	ProcedureName 765 771	biopsy
T32	Radiology 776 800	staging CT panc protocol
T33	PROBLEM 835 855	Pancreatic tail mass
T34	ProcedureName 899 902	FNB
T35	Histology 916 926	malignancy
T36	TEST 930 950	preliminary cytology
T37	PROBLEM 952 960	The mass
T38	PROBLEM 1007 1031	pancreatic duct dilation
T39	PROBLEM 1050 1058	The mass
T40	LocalInvasion 1093 1107	clear invasion
T42	PROBLEM 1168 1222	4.1x3.4cm hypoenhancing mass involving pancreatic body
T43	TREATMENT 1320 1348	Portacaval and pericaval LAD
T44	PROBLEM 1353 1360	ascites
T45	TEST 1375 1377	CT
T46	PROBLEM 1385 1417	Ill defined 10x5mm nodule in RUL
T47	PROBLEM 1462 1471	infection
T48	PROBLEM 1473 1485	inflammation
T49	Metastasis 1489 1507	metastatic disease
T50	PROBLEM 1510 1552	1.7 x 2.2 cm right breast soft tissue mass
T51	TreatmentType 1602 1618	systemic therapy
T52	PROBLEM 1623 1658	locally advanced pancreatic cancer.
T53	MedicationRegimen 1726 1736	FOLFIRINOX
T54	TREATMENT 1741 1757	locally adv PDAC
T55	TREATMENT 1769 1784	C1D1 FOLFIRINOX
T56	MedicationName 1787 1790	5FU
T57	MedicationName 1816 1827	oxaliplatin
T58	MedicationName 1839 1849	irinotecan
T59	MedicationName 1870 1878	Fulphila
T60	MedicationName 1883 1886	IVF
T61	PROBLEM 1945 1965	somewhat 
 bloody bm
T62	Symptom 2016 2024	diarrhea
T63	TREATMENT 2062 2074	chemotherapy
T64	Symptom 2095 2102	fatigue
T65	MedicationName 2129 2139	Zofran ATC
T66	MedicationName 2149 2156	imodium
T67	PROBLEM 2232 2247	bloody diarrhea
T68	PROBLEM 2278 2296	continued diarrhea
T69	PROBLEM 2298 2315	improved bleeding
T70	TEST 2318 2327	Potassium
T71	TEST 2333 2335	Mg
T72	TEST 2340 2342	Cr
T73	TEST 2352 2355	ANC
T74	TREATMENT 2371 2387	60 mEQ potassium
T75	MedicationName 2393 2396	IVF
T76	TREATMENT 2398 2403	1g Mg
T77	TEST 2423 2424	K
T78	TEST 2433 2435	Cr
T79	TREATMENT 2468 2486	20mEq PO potassium
T80	TREATMENT 2512 2526	ATC loperamide
T81	PROBLEM 2536 2544	diarrhea
T82	TEST 2581 2585	labs
T83	TEST 2598 2599	K
T84	TEST 2605 2607	Mg
T85	TEST 2613 2615	Cr
T86	TEST 2622 2625	WBC
T87	TREATMENT 2639 2651	60mEq IV KCL
T88	TREATMENT 2656 2665	Magnesium
T89	TREATMENT 2667 2672	1L NS
T90	Symptom 2675 2683	Diarrhea
T91	Symptom 2713 2720	fatigue
T92	Symptom 2722 2738	loss of appetite
T93	TREATMENT 2750 2765	C2D1 FOLFIRINOX
T94	Symptom 2795 2803	diarrhea
T95	Symptom 2836 2850	poor PO intake
T96	Symptom 2852 2859	fatigue
T97	TREATMENT 2954 2969	C2D1 FOLFIRINOX
T98	TREATMENT 3045 3058	C3 FOLFIRINOX
T99	PROBLEM 3136 3153	continued fatigue
T100	PROBLEM 3155 3180	loss of appetite diarrhea
T101	Radiology 3203 3209	CT CAP
T102	PROBLEM 3211 3233	Stable pancreatic mass
T103	PROBLEM 3239 3256	vessel encasement
T104	PROBLEM 3273 3299	distant metastatic disease
T105	ClinicalCondition 3301 3308	Colitis
T106	TEST 3312 3317	scans
T107	TREATMENT 3335 3353	FOLFOX (irinotecan
T108	ClinicalCondition 3385 3392	colitis
T109	Radiology 3396 3401	scans
T110	TREATMENT 3438 3461	FOLFOX (omit irinotecan
T111	TREATMENT 3504 3515	C5D1 FOLFOX
T112	TREATMENT 3605 3616	C6D1 FOLFOX
T113	PROBLEM 3649 3676	constant saltiness in mouth
T114	Symptom 3862 3870	diarrhea
T115	Symptom 3912 3931	throat constriction
T116	PROBLEM 4043 4047	cold
T117	TREATMENT 4105 4125	potassium rich foods
T118	TREATMENT 4151 4170	potassium repletion
T119	TREATMENT 4210 4221	these pills
T120	Symptom 4234 4252	darkening of hands
T121	Symptom 4257 4267	neuropathy
T122	Symptom 4314 4320	fevers
T123	Symptom 4322 4328	chills
T124	Symptom 4333 4339	sweats
T125	PROBLEM 4343 4350	fatigue
T126	PROBLEM 4362 4380	decreased appetite
T127	PROBLEM 4396 4407	weight loss
T128	Symptom 4431 4441	chest pain
T129	Symptom 4445 4457	palpitations
T130	Symptom 4488 4507	shortness of breath
T131	Symptom 4509 4516	dyspnea
T132	Symptom 4521 4526	cough
T133	Symptom 4555 4565	distension
T134	Symptom 4567 4571	pain
T135	Symptom 4573 4579	nausea
T136	Symptom 4581 4588	vomitin
T137	Symptom 4599 4614	bloody diarrhea
T138	Symptom 4636 4640	rash
T139	Symptom 4644 4652	jaundice
T140	Symptom 4687 4696	bone pain
T141	Symptom 4700 4708	swelling
T142	Symptom 4737 4747	neuropathy
T143	Symptom 4749 4758	headaches
T144	Symptom 4760 4774	blurred vision
T145	Symptom 4779 4788	confusion
T146	Symptom 4817 4825	bruising
T147	Symptom 4829 4837	bleeding
T148	PROBLEM 4887 4895	symptoms
T149	Symptom 4899 4906	anxiety
T150	Symptom 4910 4920	depression
T151	TEST 4927 4944	All other systems
T152	TREATMENT 4980 4999	Current Medications
T153	TREATMENT 5002 5032	Current Outpatient Medications
T154	TREATMENT 5035 5065	Medication Sig Dispense Refill
T155	TREATMENT 5070 5102	diphenoxylate-atropine (LOMOTIL)
T156	Symptom 5181 5189	Diarrhea
T157	MedicationName 5242 5264	gabapentin (NEURONTIN)
T158	TREATMENT 5359 5367	glucosam
T159	TREATMENT 5374 5410	collagen/hyalur (JOINT SUPPORT ORAL)
T160	MedicationName 5432 5457	Lactobacillus acidophilus
T161	MedicationName 5496 5516	loperamide (IMODIUM)
T162	Symptom 5573 5581	diarrhea
T163	MedicationName 5670 5688	LORazepam (ATIVAN)
T164	PROBLEM 5774 5780	nausea
T165	MedicationName 5856 5876	ondansetron (ZOFRAN)
T166	PROBLEM 5935 5941	nausea
T167	PROBLEM 5946 5954	vomiting
T168	MedicationName 5988 6008	palonosetron (Aloxi)
T169	MedicationName 6035 6063	prochlorperazine (COMPAZINE)
T170	PROBLEM 6145 6151	nausea
T171	PROBLEM 6156 6164	vomiting
T172	MedicationName 6182 6205	acetaminophen (TYLENOL)
T173	PROBLEM 6275 6279	Pain
T174	MedicationName 6287 6314	lidocaine-prilocaine (EMLA)
T175	ProcedureName 6359 6370	port access
T176	PROBLEM 6385 6389	pain
T177	MedicationName 6449 6471	oxyCODONE (ROXICODONE)
T178	Symptom 6556 6560	Pain
T179	MedicationName 6625 6657	potassium chloride (KLOR-CON 10)
T180	TREATMENT 6769 6780	medications
T181	TREATMENT 6824 6835	Medications
T182	TREATMENT 6862 6926	Medication Dose Route Frequency Provider Last Rate Last Dose   
T183	MedicationName 6933 6957	sodium chloride infusion
T184	MedicationName 7018 7056	albuterol (PROVENTIL HFA;VENTOLIN HFA)
T185	MedicationName 7141 7149	dextrose
T186	MedicationName 7270 7306	diphenhydrAMINE (BENADRYL) injection
T187	MedicationName 7365 7385	EPINEPHrine (EPIPEN)
T188	MedicationName 7458 7480	fluorouraciL (ADRUCIL)
T189	MedicationName 7493 7508	sodium chloride
T190	MedicationName 7652 7665	heparin flush
T191	TREATMENT 7757 7770	heparin flush
T192	TREATMENT 7898 7911	heparin flush
T193	MedicationName 8003 8048	hydrocortisone sodium succinate (SOLU-CORTEF)
T194	MedicationName 8131 8155	leucovorin (WELLCOVORIN)
T195	TREATMENT 8166 8174	dextrose
T196	MedicationName 8281 8299	LORazepam (ATIVAN)
T197	TREATMENT 8356 8378	oxaliplatin (ELOXATIN)
T198	MedicationName 8391 8399	dextrose
T199	TEST 8713 8719	Vitals
T200	TEST 8739 8741	BP
T201	TEST 8752 8757	Pulse
T202	TEST 8764 8768	Resp
T203	TEST 8775 8779	Temp
T204	TEST 8786 8787	C
T205	TEST 8799 8803	SpO2
T206	TEST 8811 8817	Weight
T207	TEST 8836 8842	Height
T208	PROBLEM 8920 8934	acute distress
T209	PROBLEM 8959 8970	diaphoretic
T210	PROBLEM 8994 9004	atraumatic
T211	PROBLEM 9104 9117	eye discharge
T212	PROBLEM 9122 9137	scleral icterus
T213	PROBLEM 9207 9227	respiratory distress
T214	PROBLEM 9232 9237	cough
T215	PROBLEM 9247 9267	abdominal distention
T216	PROBLEM 9291 9305	apparent edema
T217	PROBLEM 9319 9328	jaundiced
T218	PROBLEM 9334 9338	pale
T219	PROBLEM 9343 9359	visible erythema
T220	PROBLEM 9364 9376	visible rash
T221	TEST 9683 9700	latest CBC values
T222	TEST 9800 9809	WBC Count
T223	TEST 9816 9817	H
T224	TEST 9833 9843	Hemoglobin
T225	TEST 9866 9876	Hematocrit
T226	TEST 9900 9903	MCV
T227	TEST 9921 9935	Platelet Count
T228	TEST 9955 9965	Neutrophil
T229	TEST 9966 9980	Absolute Count
T230	TEST 9993 10003	Date Value
T231	TEST 10071 10078	Albumin
T232	TEST 10080 10085	Serum
T233	TEST 10088 10094	Plasma
T234	TEST 10113 10133	Alkaline Phosphatase
T235	TEST 10156 10176	Alanine transaminase
T236	TEST 10194 10216	Aspartate transaminase
T237	TEST 10234 10243	Bilirubin
T238	TEST 10245 10250	Total
T239	TEST 10269 10282	Urea Nitrogen
T240	TEST 10284 10298	Serum / Plasma
T241	TEST 10316 10323	Calcium
T242	TEST 10332 10337	Serum
T243	TEST 10340 10346	Plasma
T244	TEST 10365 10373	Chloride
T245	TEST 10375 10380	Serum
T246	TEST 10383 10389	Plasma
T247	TEST 10408 10422	Carbon Dioxide
T248	TEST 10447 10456	Anion Gap
T249	TEST 10474 10484	Creatinine
T250	TEST 10508 10512	eGFR
T251	TEST 10554 10558	eGFR
T252	TEST 10562 10569	African
T253	TEST 10570 10574	Amer
T254	TEST 10592 10599	Glucose
T255	TEST 10601 10612	non-fasting
T256	TEST 10631 10640	Potassium
T257	TEST 10642 10647	Serum
T258	TEST 10650 10656	Plasma
T259	TEST 10662 10664	LL
T260	TEST 10680 10686	Sodium
T261	TEST 10688 10693	Serum
T262	TEST 10696 10702	Plasma
T263	TEST 10721 10728	Protein
T264	TEST 10730 10735	Total
T265	TEST 10737 10742	Serum
T266	TEST 10745 10751	Plasma
T267	TEST 10817 10825	Normaliz
T268	TEST 10826 10831	Ratio
T269	TEST 10850 10852	PT
T270	PROBLEM 10897 10900	HCV
T271	TEST 10995 11000	HBCAB
T272	TEST 11019 11024	HBSAG
T273	TEST 11044 11050	Cancer
T274	TEST 11051 11058	Antigen
T275	TEST 11066 11076	Date Value
T276	TEST 11087 11093	Status
T277	TEST 11241 11265	Carcinoembryonic Antigen
T278	TEST 11289 11295	Status
T279	TEST 11372 11424	Architect Chemiluminescent Microparticle Immunoassay
T280	TEST 11500 11538	the patient's relevant imaging studies
T281	TEST 11616 11648	Ct Abdomen /pelvis With Contrast
T282	TEST 11679 11681	CT
T283	TEST 11682 11710	ABDOMEN/PELVIS WITH CONTRAST
T284	TEST 11756 11771	Restaging scans
T285	PROBLEM 11773 11790	Pancreatic cancer
T286	TEST 11804 11821	CT abdomen/pelvis
T287	TEST 11907 11950	contiguous 1.25-mm collimation axial images
T288	TEST 11997 12027	Coronal and sagittal reformats
T289	TREATMENT 12064 12104	Intravenous and oral iodinated contrasts
T290	TEST 12162 12176	chest findings
T291	TEST 12225 12244	the CT of the chest
T292	PROBLEM 12271 12296	Diffuse hepatic steatosis
T293	PROBLEM 12298 12338	Heterogeneous and diminished enhancement
T294	PROBLEM 12340 12383	Mild intrahepatic biliary ductal dilatation
T295	PROBLEM 12444 12480	4.4 x 3.5 cm mass in pancreatic body
T296	PROBLEM 12508 12545	upstream pancreatic ductal dilatation
T297	PROBLEM 12550 12569	parenchymal atrophy
T298	TEST 12582 12593	prior study
T299	PROBLEM 12674 12693	Small hiatal hernia
T300	PROBLEM 12695 12713	Diffuse wall edema
T301	PROBLEM 12763 12774	obstruction
T302	PROBLEM 12790 12841	Encasement and obstruction of the portal confluence
T303	PROBLEM 12845 12864	the pancreatic mass
T304	PROBLEM 12871 12921	further attenuation of right and left portal veins
T305	PROBLEM 12923 12979	Encasement of celiac axis and superior mesenteric artery
T306	PROBLEM 12986 13019	severe stenosis of hepatic artery
T307	PROBLEM 13076 13091	Lymphadenopathy
T308	PROBLEM 13093 13138	Several periportal/peripancreatic lymph nodes
T309	TEST 13180 13191	prior study
T310	PROBLEM 13205 13215	Mild edema
T311	PROBLEM 13220 13250	trace ascites in upper abdomen
T312	PROBLEM 13316 13376	Multilevel degenerative changes in thoracic and lumbar spine
T313	PROBLEM 13383 13431	grade 1 anterolisthesis of L3 on L4 and L4 on L5
T314	PROBLEM 13433 13461	Extraperitoneal soft tissues
T315	PROBLEM 13463 13495	Substantial interval weight loss
T316	TREATMENT 13497 13509	Lines/drains
T317	TEST 13601 13612	CTDIvol Max
T318	PROBLEM 13729 13744	Pancreatic mass
T319	PROBLEM 13769 13843	encasement and severe narrowing of celiac and superior mesenteric arteries
T320	PROBLEM 13848 13880	Ascending and transverse colitis
T321	TEST 13980 14010	Biomedical Imaging    Ct Chest
T322	TEST 14053 14055	CT
T323	PROBLEM 14095 14120	Cancer metastatic to lung
T324	PROBLEM 14196 14207	lung cancer
T325	TEST 14208 14223	Restaging scans
T326	TEST 14259 14304	Serial 1.25 mm axial images through the chest
T327	TREATMENT 14347 14367	intravenous contrast
T328	TEST 14438 14449	CTDIvol Max
T329	PROBLEM 14574 14631	Unchanged right upper lobe mixed solid groundglass nodule
T330	PROBLEM 14677 14699	Unchanged nodular scar
T331	PROBLEM 14703 14714	atelectasis
T332	PROBLEM 14727 14741	the osteophyte
T333	PROBLEM 14777 14788	new nodules
T334	PROBLEM 14836 14865	intrathoracic lymphadenopathy
T335	TEST 14869 14885	CT size criteria
T336	PROBLEM 14887 14938	Heterogeneous appearance of the right thyroid gland
T337	TREATMENT 14974 14994	New right chest port
T338	TREATMENT 15000 15029	tip in the lower right atrium
T339	PROBLEM 15031 15082	Unchanged mild flattening of the ventricular septum
T340	PROBLEM 15103 15134	increased right heart pressures
T341	PROBLEM 15159 15210	suspicious bone or soft tissue lesions in the chest
T342	TEST 15245 15273	CT of the abdomen and pelvis
T343	TEST 15298 15322	intra-abdominal findings
T344	PROBLEM 15334 15416	significant interval change in right upper lobe mixed solid and groundglass nodule
T345	PROBLEM 15458 15466	scarring
T346	PROBLEM 15468 15489	primary lung neoplasm
T347	PROBLEM 15504 15528	pulmonary adenocarcinoma
T348	PROBLEM 15534 15552	metastatic disease
T349	TEST 15556 15578	Continued surveillance
T350	TEST 15759 15762	FNA
T351	PROBLEM 15763 15783	Pancreatic Tail Mass
T352	PROBLEM 15788 15806	Pancreas tail mass
T353	TEST 15808 15829	Endoscopic ultrasound
T354	TEST 15837 15867	fine needle  aspiration biopsy
T355	PROBLEM 15869 15883	Adenocarcinoma
T356	TEST 15911 15932	The aspirate material
T357	PROBLEM 15939 15980	invasive ductal carcinoma of the pancreas
T358	TEST 15983 16003	Immunohistochemistry
T359	TREATMENT 16044 16095	DNA  mismatch repair protein expression on block A1
T360	PROBLEM 16332 16353	locally advanced PDAC
T361	MedicationRegimen 16357 16368	mFOLFIRINOX
T362	TreatmentType 16450 16470	upfront chemotherapy
T363	TEST 16476 16486	q2mo scans
T364	TreatmentType 16514 16536	induction chemotherapy
T365	PROBLEM 16658 16665	disease
T366	MarginStatus 16699 16714	an R0 resection
T367	RadiationTherapyName 16722 16750	consolidative chemoradiation
T368	RadiationTherapyName 16758 16793	conventionally fractionated therapy
T369	MedicationName 16799 16822	concurrent capecitabine
T370	TREATMENT 16826 16843	a radiosensitizer
T371	RadiationTherapyName 16848 16852	SBRT
T372	ProcedureName 16902 16909	surgery
T373	TREATMENT 16920 16940	induction FOLFIRINOX
T374	ClinicalCondition 17089 17096	colitis
T375	Symptom 17102 17117	bloody diarrhea
T376	ClinicalCondition 17119 17126	low ANC
T377	Symptom 17128 17147	decreased PO intake
T378	ClinicalCondition 17152 17163	hypokalemia
T379	TREATMENT 17174 17192	2x IVF in infusion
T380	TREATMENT 17198 17219	addition IV potassium
T381	MedicationName 17242 17252	irinotecan
T382	PROBLEM 17269 17279	delayed C2
T383	MedicationName 17308 17316	Fulphila
T384	TREATMENT 17321 17342	growth factor support
T385	Symptom 17391 17409	persistent fatigue
T386	Symptom 17411 17424	poor appetite
T387	Symptom 17426 17437	weight loss
T388	PROBLEM 17511 17534	her frequent trt delays
T389	TEST 17547 17549	CA
T390	Radiology 17594 17600	CT CAP
T391	PROBLEM 17637 17651	stable disease
T392	PROBLEM 17672 17690	distant metastases
T393	ClinicalCondition 17714 17721	colitis
T394	PROBLEM 17746 17758	her diarrhea
T395	TREATMENT 17836 17863	subsequent cycles of FOLFOX
T396	PROBLEM 17888 17909	Locally Advanced PDAC
T397	TEST 17914 17918	Labs
T398	TEST 17920 17922	PS
T399	TREATMENT 17930 17944	C6D1 treatment
T400	PROBLEM 17963 17990	Omitted irinotecan since C3
T401	PROBLEM 17999 18006	colitis
T402	Radiology 18010 18015	scans
T403	MedicationRegimen 18058 18064	FOLFOX
T404	MedicationName 18088 18099	oxaliplatin
T405	MedicationName 18109 18112	5FU
T406	MedicationName 18135 18140	Aloxi
T407	MedicationName 18142 18152	aprepitant
T408	MedicationName 18154 18167	dexamethasone
T409	TreatmentType 18171 18178	premeds
T410	TREATMENT 18185 18198	prn ativan D1
T411	TREATMENT 18205 18207	NS
T412	TREATMENT 18214 18230	PO dexamethasone
T413	MedicationName 18236 18242	Zofran
T414	MedicationName 18244 18250	ativan
T415	Datetime 18254 18256	D3
T416	TREATMENT 18264 18275	D3 Fulphila
T417	TEST 18282 18285	ANC
T418	TEST 18308 18315	pt's CA
T419	ClinicalCondition 18346 18353	colitis
T420	Radiology 18382 18387	scans
T421	Symptom 18425 18433	Diarrhea
T422	Radiology 18503 18505	CT
T423	PROBLEM 18532 18539	colitis
T424	TREATMENT 18554 18564	irinotecan
T425	MedicationName 18647 18657	loperamide
T426	ClinicalCondition 18666 18691	Electrolyte Abnormalities
T427	MedicationName 18714 18722	20mEq IV
T428	TREATMENT 18742 18763	Klor Con 10 mEq pills
T429	TEST 18792 18793	K
T430	TEST 18798 18800	Mg
T431	MedicationName 18808 18826	20mEq IV +40mEq PO
T432	TREATMENT 18836 18857	Klor Con 10 mEq pills
T433	TEST 18867 18868	K
T434	TEST 19084 19100	renal evaluation
T435	ClinicalCondition 19108 19111	RTA
T436	ClinicalCondition 19124 19135	hypokalemia
T437	TREATMENT 19188 19215	liquid K and MicroK neither
T438	Symptom 19249 19260	Weight loss
T439	ClinicalCondition 19415 19421	nodule
T440	TEST 19435 19457	diagnostic 
 mammogram
T441	Radiology 19474 19483	mammogram
T442	GenomicTest 19542 19557	genetic testing
T443	TREATMENT 19823 19841	the treatment plan
T444	PROBLEM 19846 19854	symptoms
T445	Age 34 36	73
T446	ClinicalCondition 161 178	pancreatic cancer
A1	ChronicVal T446 chronic
A2	ContinuityVal T446 unclear
T447	LocalInvasion 144 160	locally advanced
R1	TumorDesc TumorDetails:T446 Desc:T447	
T448	Datetime 203 211	07/08/19
T449	Symptom 249 258	PO intake
A3	IsPresentOnFirstCancerDiagnosis T449 yes
A4	IsCausedByDiagnosedCancer T449 yes
A5	ChronicVal T449 non-chronic
A6	ContinuityVal T449 new
R2	HappensBefore Arg1:T448 Arg2:T449	
T450	Symptom 271 291	abdominal discomfort
A7	IsPresentOnFirstCancerDiagnosis T450 yes
A8	IsCausedByDiagnosedCancer T450 yes
A9	ChronicVal T450 non-chronic
A10	ContinuityVal T450 new
T451	ClinicalCondition 300 308	diabetes
A11	IsPresentOnFirstCancerDiagnosis T451 yes
A12	IsCausedByDiagnosedCancer T451 yes
A13	ChronicVal T451 non-chronic
A14	ContinuityVal T451 new
A15	IntentVal T22 diagnosis
T452	Size 374 383	3.1x2.1cm
A16	EpisodeDescription T452 FirstOccurrence
T453	RadPathResult 396 400	mass
A17	RadPathResultVal T453 InitialCancerDiagnosis
R3	TestOrProcedureReveals Test:T22 Desc:T452	
R4	ResultOfTest Desc:T453 Test:T22	
T454	Site 404 419	pancreatic body
R5	SiteOf Arg1:T454 Arg2:T453	
A18	RadPathResultVal T24 InitialCancerDiagnosis
A19	RadPathResultVal T25 InitialCancerDiagnosis
T455	LocalInvasion 461 471	encasement
A20	RadPathResultVal T455 Others
T456	Site 475 486	celiac axis
T457	Site 488 491	CHA
T458	Site 493 523	proximal splenic        artery
R6	SiteOf Arg1:T456 Arg2:T455	
R7	SiteOf Arg1:T457 Arg2:T455	
R8	SiteOf Arg1:T458 Arg2:T455	
R9	ResultOfTest Desc:T455 Test:T22	
T459	LocalInvasion 537 545	abutment
T460	Site 553 578	portal splenic confluence
R10	SiteOf Arg1:T460 Arg2:T459	
R11	TestOrProcedureReveals Test:T22 Desc:T459	
T461	LymphNodeInvolvement 655 657	LN
A21	NegationModalityVal T461 uncertain_in_present
A22	EpisodeDescription T461 FirstOccurrence
T462	Site 626 639	gastrohepatic
T463	Site 644 654	periportal
R12	SiteOf Arg1:T462 Arg2:T461	
R13	SiteOf Arg1:T463 Arg2:T461	
T464	Size 664 669	1.5cm
R14	TestOrProcedureReveals Test:T22 Desc:T461	
A23	RadPathResultVal T29 Others
R15	ResultOfTest Desc:T29 Test:T22	
R16	HappensAtOnDuring Arg1:T448 Arg2:T22	
T465	Datetime 690 698	08/02/19
A24	NegationModalityVal T30 planned_in_future
A25	IntentVal T30 diagnosis
A26	NegationModalityVal T31 planned_in_future
A27	IntentVal T31 diagnosis
A28	IntentVal T32 staging
A29	NegationModalityVal T32 planned_in_future
R17	HappensAtOnDuring Arg1:T465 Arg2:T30	
R18	HappensAtOnDuring Arg1:T465 Arg2:T31	
R19	HappensAtOnDuring Arg1:T465 Arg2:T32	
T466	Datetime 802 810	09/09/19
T467	ProcedureName 812 815	EUS
A30	NegationModalityVal T467 affirmed
A31	IntentVal T467 diagnosis
T468	RadPathResult 851 855	mass
A32	RadPathResultVal T468 InitialCancerDiagnosis
T469	Site 835 850	Pancreatic tail
R20	SiteOf Arg1:T469 Arg2:T468	
R21	ResultOfTest Desc:T468 Test:T467	
T470	Size 875 893	23.6 mm by 18.2 mm
A33	EpisodeDescription T470 FirstOccurrence
R22	TestOrProcedureReveals Test:T467 Desc:T470	
A34	IntentVal T34 diagnosis
R23	TestOrProcedureReveals Test:T34 Desc:T35	
T471	RadPathResult 956 960	mass
A35	RadPathResultVal T471 InitialCancerDiagnosis
T472	RadPathResult 1054 1058	mass
A36	RadPathResultVal T472 InitialCancerDiagnosis
T473	LocalInvasion 961 968	invaded
A37	RadPathResultVal T473 Others
T474	LocalInvasion 1059 1066	abutted
A38	RadPathResultVal T474 Others
R24	TestOrProcedureReveals Test:T467 Desc:T473	
R25	TestOrProcedureReveals Test:T467 Desc:T474	
T475	Site 978 998	main pancreatic duct
A39	RadPathResultVal T475 Others
T476	Site 1071 1084	celiac artery
A40	RadPathResultVal T476 Others
T477	RadPathResult 1023 1031	dilation
A41	RadPathResultVal T477 Others
T478	Site 1007 1022	pancreatic duct
T479	Site 1036 1048	splenic vein
R26	SiteOf Arg1:T479 Arg2:T477	
R27	SiteOf Arg1:T478 Arg2:T477	
R28	NotUndergoneBecauseOf Arg1:T467 Reason:T477	
R29	SiteOf Arg1:T475 Arg2:T473	
R30	ResultOfTest Desc:T471 Test:T467	
R31	SiteOf Arg1:T476 Arg2:T474	
R32	ResultOfTest Desc:T472 Test:T467	
A42	NegationModalityVal T474 uncertain_in_present
T480	Site 1124 1127	SMV
T481	Site 1277 1280	SMA
T482	Site 1282 1285	SMV
T41	Datetime 1131 1139	09/24/19
A43	NegationModalityVal T40 negated
R33	TestOrProcedureReveals Test:T467 Desc:T40	
T483	LocalInvasion 1112 1119	encased
R34	SiteOf Arg1:T480 Arg2:T483	
T484	Radiology 1141 1166	CT AP Pancreatic Protocol
A44	IntentVal T484 staging
T485	Size 1168 1177	4.1x3.4cm
A45	EpisodeDescription T485 FirstOccurrence
T486	RadPathResult 1178 1196	hypoenhancing mass
A46	RadPathResultVal T486 InitialCancerDiagnosis
T487	Site 1207 1222	pancreatic body
R35	SiteOf Arg1:T487 Arg2:T486	
R36	TestOrProcedureReveals Test:T484 Desc:T485	
R37	ResultOfTest Desc:T486 Test:T484	
T488	Size 1233 1242	4.1x3.4cm
A47	EpisodeDescription T488 FirstOccurrence
A48	RadPathResultVal T480 Others
T489	Site 1264 1275	celiac axis
A49	RadPathResultVal T489 Others
T490	Site 1287 1301	splenic artery
A50	RadPathResultVal T490 Others
T491	Site 1306 1318	splenic vein
A51	RadPathResultVal T491 Others
T492	LocalInvasion 1244 1263	completely encasing
A52	EpisodeDescription T492 FirstOccurrence
R38	SiteOf Arg1:T489 Arg2:T492	
R39	SiteOf Arg1:T481 Arg2:T492	
R40	SiteOf Arg1:T482 Arg2:T492	
R41	SiteOf Arg1:T490 Arg2:T492	
R42	SiteOf Arg1:T491 Arg2:T492	
R43	TestOrProcedureReveals Test:T484 Desc:T492	
R44	TestOrProcedureReveals Test:T484 Desc:T488	
T493	LymphNodeInvolvement 1345 1348	LAD
A53	EpisodeDescription T493 FirstOccurrence
T494	Site 1335 1344	pericaval
T495	Site 1320 1330	Portacaval
R45	SiteOf Arg1:T494 Arg2:T493	
R46	SiteOf Arg1:T495 Arg2:T493	
R47	TestOrProcedureReveals Test:T484 Desc:T493	
T496	RadPathResult 1353 1360	ascites
A54	NegationModalityVal T496 negated
R48	ResultOfTest Desc:T496 Test:T484	
T497	Datetime 1365 1373	09/24/19
T498	Radiology 1375 1383	CT chest
A55	IntentVal T498 staging
R49	HappensAtOnDuring Arg1:T497 Arg2:T498	
T499	Size 1397 1403	10x5mm
A56	NegationModalityVal T499 uncertain_in_present
A57	EpisodeDescription T499 FirstOccurrence
T500	RadPathResult 1404 1410	nodule
A58	RadPathResultVal T500 Unclear
R50	ResultOfTest Desc:T500 Test:T498	
T501	Site 1414 1417	RUL
R51	SiteOf Arg1:T501 Arg2:T499	
R52	TestOrProcedureReveals Test:T498 Desc:T499	
A59	NegationModalityVal T49 uncertain_in_present
A60	EpisodeDescription T49 FirstOccurrence
R53	TestOrProcedureReveals Test:T498 Desc:T49	
T502	Size 1510 1522	1.7 x 2.2 cm
T503	Site 1529 1535	breast
T504	Laterality 1523 1528	right
T505	RadPathResult 1536 1552	soft tissue mass
A61	RadPathResultVal T505 Others
R54	SiteOf Arg1:T503 Arg2:T505	
R55	LateralityOfSite Arg1:T504 Arg2:T503	
A62	NegationModalityVal T502 negated
T506	Datetime 1554 1562	09/27/19
A63	NegationModalityVal T51 planned_in_future
A64	TreatmentContinuityVal T51 planned
A65	TreatmentTypeVal T51 maintenance
A66	TreatmentIntentVal T51 palliative
T507	ClinicalCondition 1640 1657	pancreatic cancer
T508	LocalInvasion 1623 1639	locally advanced
A69	EpisodeDescription T508 FirstOccurrence
R56	TumorDesc TumorDetails:T508 Desc:T507	
R57	TreatmentAdministeredForProblem Treatment:T51 Prob:T507	
R58	HappensAtOnDuring Arg1:T506 Arg2:T51	
T509	Datetime 1661 1669	10/01/19
A70	TreatmentContinuityVal T53 planned
A71	TreatmentTypeVal T53 maintenance
A72	TreatmentIntentVal T53 palliative
T510	LocalInvasion 1741 1752	locally adv
A73	EpisodeDescription T510 FirstOccurrence
A67	EpisodeDescription T507 FirstOccurrence
A68	ChronicVal T507 non-chronic
A74	ContinuityVal T507 new
T511	ClinicalCondition 1753 1757	PDAC
A75	ChronicVal T511 non-chronic
A76	ContinuityVal T511 new
A77	EpisodeDescription T511 FirstOccurrence
R59	TumorDesc TumorDetails:T510 Desc:T511	
R60	TreatmentAdministeredForProblem Treatment:T53 Prob:T511	
T512	Datetime 1759 1767	10/22/19
R61	HappensAtOnDuring Arg1:T509 Arg2:T53	
T513	MedicationRegimen 1774 1784	FOLFIRINOX
A78	TreatmentContinuityVal T513 started
A79	TreatmentTypeVal T513 maintenance
A80	TreatmentIntentVal T513 palliative
T514	MedicationRegimen 2755 2765	FOLFIRINOX
A81	TreatmentContinuityVal T514 discontinued_early
A82	TreatmentTypeVal T514 maintenance
A83	TreatmentIntentVal T514 palliative
T515	MedicationRegimen 2959 2969	FOLFIRINOX
A84	TreatmentContinuityVal T515 continuing
A85	TreatmentTypeVal T515 maintenance
A86	TreatmentIntentVal T515 palliative
T516	MedicationRegimen 3048 3058	FOLFIRINOX
A87	TreatmentContinuityVal T516 continuing
A88	TreatmentTypeVal T516 maintenance
A89	TreatmentIntentVal T516 palliative
T517	MedicationRegimen 3335 3341	FOLFOX
A90	TreatmentContinuityVal T517 continuing
A91	TreatmentTypeVal T517 maintenance
A92	TreatmentIntentVal T517 palliative
T518	MedicationRegimen 3438 3444	FOLFOX
A93	TreatmentContinuityVal T518 continuing
A94	TreatmentTypeVal T518 maintenance
A95	TreatmentIntentVal T518 palliative
T519	MedicationRegimen 3610 3616	FOLFOX
A96	TreatmentContinuityVal T519 continuing
A97	TreatmentTypeVal T519 maintenance
A98	TreatmentIntentVal T519 palliative
T520	Cycles 1769 1773	C1D1
T521	Cycles 2750 2754	C2D1
T522	Cycles 2954 2958	C2D1
T523	Cycles 3045 3047	C3
T524	Cycles 3330 3334	C3D1
T525	Cycles 3433 3437	C4D1
T526	Cycles 3469 3470	3
T527	Cycles 3605 3609	C6D1
T528	Cycles 3541 3542	3
A99	TreatmentContinuityVal T56 started
A100	TreatmentTypeVal T56 maintenance
A101	TreatmentIntentVal T56 palliative
A102	TreatmentCategory T56 AntiNeoPlastics
A103	TreatmentContinuityVal T57 started
A104	TreatmentTypeVal T57 maintenance
A105	TreatmentIntentVal T57 palliative
A106	TreatmentCategory T57 AntiNeoPlastics
A107	TreatmentContinuityVal T58 started
A108	TreatmentTypeVal T58 maintenance
A109	TreatmentIntentVal T58 palliative
A110	TreatmentCategory T58 AntiNeoPlastics
T529	MedicationName 3343 3353	irinotecan
A111	TreatmentContinuityVal T529 discontinued_early
A112	TreatmentTypeVal T529 maintenance
A113	TreatmentIntentVal T529 palliative
A114	TreatmentCategory T529 AntiNeoPlastics
T530	MedicationName 3451 3461	irinotecan
A115	TreatmentContinuityVal T530 started
A116	TreatmentTypeVal T530 maintenance
A117	TreatmentIntentVal T530 palliative
A118	TreatmentCategory T530 AntiNeoPlastics
T531	MedicationName 3523 3533	irinotecan
A119	TreatmentContinuityVal T531 started
A120	TreatmentTypeVal T531 maintenance
A121	TreatmentIntentVal T531 palliative
A122	TreatmentCategory T531 AntiNeoPlastics
T532	TreatmentDosage 1828 1836	85 mg/m2
T533	TreatmentDosage 1850 1859	180 mg/m2
T534	TreatmentDosage 2371 2377	60 mEQ
T535	TreatmentDosage 2468 2473	20mEq
T536	Symptom 3803 3825	lost additional weight
A123	IsPresentOnFirstCancerDiagnosis T536 unclear
A124	IsCausedByDiagnosedCancer T536 yes
A125	ChronicVal T536 non-chronic
A126	ContinuityVal T536 stable
T537	Symptom 3155 3171	loss of appetite
A128	IsCausedByDiagnosedCancer T537 no
A129	ChronicVal T537 non-chronic
A130	ContinuityVal T537 stable
T538	Symptom 3172 3180	diarrhea
A132	IsCausedByDiagnosedCancer T538 no
A133	ChronicVal T538 non-chronic
A134	ContinuityVal T538 stable
T539	Symptom 3146 3153	fatigue
A127	IsCausedByDiagnosedCancer T539 no
A131	ChronicVal T539 non-chronic
A135	ContinuityVal T539 stable
A136	IsCausedByDiagnosedCancer T94 no
A137	ChronicVal T94 non-chronic
A138	ContinuityVal T94 stopped
A139	IsCausedByDiagnosedCancer T95 no
A140	ChronicVal T95 non-chronic
A141	ContinuityVal T95 stable
A142	IsCausedByDiagnosedCancer T96 no
A143	ChronicVal T96 non-chronic
A144	ContinuityVal T96 stable
A145	IsCausedByDiagnosedCancer T92 no
A146	ChronicVal T92 non-chronic
A147	ContinuityVal T92 stable
A148	IsCausedByDiagnosedCancer T91 no
A149	ChronicVal T91 non-chronic
A150	ContinuityVal T91 stable
A151	IsCausedByDiagnosedCancer T90 no
A152	ChronicVal T90 non-chronic
A153	ContinuityVal T90 stopped
R62	ResultOfTest Desc:T24 Test:T22	
R63	ResultOfTest Desc:T25 Test:T22	
R64	HappensAtOnDuring Arg1:T467 Arg2:T466	
A154	TreatmentContinuityVal T59 started
A155	TreatmentTypeVal T59 others
A156	TreatmentIntentVal T59 others
A157	TreatmentCategory T59 Supportive
A158	TreatmentContinuityVal T60 started
A159	TreatmentTypeVal T60 others
A160	TreatmentIntentVal T60 others
A161	TreatmentCategory T60 Supportive
T540	TreatmentDosage 1791 1800	2400mg/m2
R65	BeginsOnOrAt Arg1:T512 Arg2:T513	
R66	TreatmentDesc Therapy:T520 Desc:T513	
R67	TreatmentDesc Therapy:T56 Desc:T540	
R68	TreatmentDesc Therapy:T57 Desc:T532	
R69	TreatmentDesc Therapy:T58 Desc:T533	
T541	Datetime 1894 1902	10/27/19
R71	SizeOf Arg1:T464 Arg2:T461	
R72	SizeOf Arg1:T470 Arg2:T468	
T542	Symptom 1956 1965	bloody bm
A162	IsPresentOnFirstCancerDiagnosis T542 no
A163	IsCausedByDiagnosedCancer T542 unclear
A164	ChronicVal T542 non-chronic
A165	ContinuityVal T542 new
R73	HappensAtOnDuring Arg1:T541 Arg2:T542	
T543	Symptom 1987 2014	decreased/minimal PO intake
A166	IsPresentOnFirstCancerDiagnosis T543 no
A167	IsCausedByDiagnosedCancer T543 unclear
A168	ChronicVal T543 non-chronic
A169	ContinuityVal T543 new
R74	SizeOf Arg1:T485 Arg2:T486	
R75	SizeOf Arg1:T488 Arg2:T486	
R76	SizeOf Arg1:T499 Arg2:T500	
A170	IsPresentOnFirstCancerDiagnosis T62 no
A171	IsCausedByDiagnosedCancer T62 unclear
A172	ChronicVal T62 non-chronic
A173	ContinuityVal T62 new
R77	SizeOf Arg1:T502 Arg2:T505	
R78	ConditionOrTreatmentCausesProblem Treatment:T513 Prob:T542	
R79	ConditionOrTreatmentCausesProblem Treatment:T513 Prob:T543	
R80	ConditionOrTreatmentCausesProblem Treatment:T513 Prob:T62	
A174	IsPresentOnFirstCancerDiagnosis T64 no
A175	IsCausedByDiagnosedCancer T64 unclear
A176	ChronicVal T64 non-chronic
A177	ContinuityVal T64 new
A178	TreatmentContinuityVal T65 started
A179	TreatmentTypeVal T65 others
A180	TreatmentIntentVal T65 others
A181	TreatmentCategory T65 Supportive
A182	TreatmentContinuityVal T66 started
A183	TreatmentTypeVal T66 others
A184	TreatmentIntentVal T66 others
A185	TreatmentCategory T66 Supportive
T544	Symptom 2232 2247	bloody diarrhea
A186	IsPresentOnFirstCancerDiagnosis T544 no
A187	IsCausedByDiagnosedCancer T544 unclear
A188	ChronicVal T544 non-chronic
A189	ContinuityVal T544 new
R81	TreatmentAdministeredForProblem Treatment:T66 Prob:T544	
R82	TreatmentAdministeredForProblem Treatment:T65 Prob:T543	
R83	HappensAtOnDuring Arg1:T41 Arg2:T484	
T545	Symptom 2288 2296	diarrhea
T546	Symptom 2307 2315	bleeding
A194	IsPresentOnFirstCancerDiagnosis T546 no
A195	IsCausedByDiagnosedCancer T546 no
A196	ChronicVal T546 non-chronic
A197	ContinuityVal T546 improving
T547	MedicationName 2378 2387	potassium
A198	TreatmentContinuityVal T547 finished
A199	TreatmentTypeVal T547 others
A200	TreatmentIntentVal T547 others
A201	TreatmentCategory T547 Supportive
A202	TreatmentContinuityVal T75 finished
A203	TreatmentTypeVal T75 others
A204	TreatmentIntentVal T75 others
A205	TreatmentCategory T75 Supportive
T548	MedicationName 2401 2403	Mg
A206	TreatmentContinuityVal T548 finished
A207	TreatmentTypeVal T548 others
A208	TreatmentIntentVal T548 others
A209	TreatmentCategory T548 Supportive
T549	MedicationName 2656 2665	Magnesium
A210	TreatmentContinuityVal T549 finished
A211	TreatmentTypeVal T549 others
A212	TreatmentIntentVal T549 others
A213	TreatmentCategory T549 Supportive
T550	MedicationName 2648 2651	KCL
A214	TreatmentContinuityVal T550 finished
A215	TreatmentTypeVal T550 others
A216	TreatmentIntentVal T550 others
A217	TreatmentCategory T550 Supportive
T551	MedicationName 2512 2526	ATC loperamide
A218	TreatmentContinuityVal T551 started
A219	TreatmentTypeVal T551 others
A220	TreatmentIntentVal T551 others
A221	TreatmentCategory T551 Supportive
T552	TreatmentDosage 2398 2400	1g
T553	TreatmentDosage 2639 2647	60mEq IV
T554	TreatmentDosage 2653 2655	1g
T555	TreatmentDosage 2667 2669	1L
R84	ConditionOrTreatmentCausesProblem Treatment:T513 Prob:T545	
R85	TreatmentAdministeredForProblem Treatment:T551 Prob:T545	
A190	IsPresentOnFirstCancerDiagnosis T545 no
A191	IsCausedByDiagnosedCancer T545 no
A192	ChronicVal T545 non-chronic
A193	ContinuityVal T545 stable
T556	Symptom 2536 2544	diarrhea
A222	IsPresentOnFirstCancerDiagnosis T556 no
A223	IsCausedByDiagnosedCancer T556 no
A224	ChronicVal T556 non-chronic
A225	ContinuityVal T556 stable
A226	NegationModalityVal T556 hypothetical_in_future
T557	Datetime 2551 2559	11/05/19
T558	Datetime 2259 2267	10/29/19
R86	HappensAtOnDuring Arg1:T558 Arg2:T545	
R87	HappensAtOnDuring Arg1:T558 Arg2:T546	
R88	HappensAtOnDuring Arg1:T558 Arg2:T547	
R89	TreatmentDesc Therapy:T534 Desc:T547	
R90	HappensAtOnDuring Arg1:T558 Arg2:T75	
R91	BeginsOnOrAt Arg1:T558 Arg2:T548	
R92	TreatmentDesc Therapy:T552 Desc:T548	
T559	MedicationName 2474 2486	PO potassium
A227	TreatmentContinuityVal T559 finished
A228	TreatmentTypeVal T559 others
A229	TreatmentIntentVal T559 others
A230	TreatmentCategory T559 Supportive
R93	TreatmentDesc Therapy:T535 Desc:T559	
R94	TreatmentAdministeredForProblem Treatment:T551 Prob:T556	
R95	HappensAtOnDuring Arg1:T557 Arg2:T550	
R96	HappensAtOnDuring Arg1:T557 Arg2:T549	
R97	TreatmentDesc Therapy:T553 Desc:T550	
R98	TreatmentDesc Therapy:T554 Desc:T549	
T560	MedicationName 2670 2672	NS
A231	TreatmentContinuityVal T560 finished
A232	TreatmentTypeVal T560 others
A233	TreatmentIntentVal T560 others
A234	TreatmentCategory T560 Supportive
R99	TreatmentDesc Therapy:T555 Desc:T560	
R100	EndsOnOrAt Arg1:T557 Arg2:T90	
R101	HappensAtOnDuring Arg1:T557 Arg2:T91	
R102	HappensAtOnDuring Arg1:T557 Arg2:T92	
T561	Datetime 2740 2748	11/12/19
R103	HappensAtOnDuring Arg1:T561 Arg2:T514	
R104	HappensBefore Arg1:T448 Arg2:T450	
R105	TreatmentDesc Therapy:T521 Desc:T514	
R106	HappensBefore Arg1:T448 Arg2:T451	
R107	TreatmentDiscontinuedBecauseOf Therapy:T514 Reason:T95	
R108	TreatmentDiscontinuedBecauseOf Therapy:T514 Reason:T96	
R109	TreatmentDesc Therapy:T522 Desc:T515	
T562	Datetime 3035 3043	12/03/19
T563	Datetime 2944 2952	11/19/19
R110	HappensAtOnDuring Arg1:T563 Arg2:T515	
R111	HappensAtOnDuring Arg1:T562 Arg2:T516	
R112	TreatmentDesc Therapy:T523 Desc:T516	
R113	ConditionOrTreatmentCausesProblem Treatment:T516 Prob:T539	
R114	ConditionOrTreatmentCausesProblem Treatment:T516 Prob:T537	
R115	TreatmentAdministeredForProblem Treatment:T516 Prob:T538	
T564	Cycles 3187 3188	2
T565	Datetime 3193 3201	12/10/19
A235	IntentVal T101 TreatmentAssessment
T566	DiseaseState 3211 3217	Stable
A236	DiseaseStateVal T566 stability
T567	RadPathResult 3229 3233	mass
A237	RadPathResultVal T567 DiseaseStability
R116	ResultOfTest Desc:T567 Test:T101	
R117	TestOrProcedureReveals Test:T101 Desc:T566	
T568	LocalInvasion 3246 3256	encasement
A238	EpisodeDescription T568 FirstOccurrence
R118	TestOrProcedureReveals Test:T101 Desc:T568	
T569	Site 3239 3245	vessel
R119	SiteOf Arg1:T569 Arg2:T568	
T570	Metastasis 3281 3291	metastatic
A239	NegationModalityVal T570 negated
R120	TestOrProcedureReveals Test:T101 Desc:T570	
R121	HappensAtOnDuring Arg1:T565 Arg2:T101	
R122	TreatmentDesc Therapy:T514 Desc:T564	
A240	ChronicVal T105 non-chronic
A241	ContinuityVal T105 new
R123	TestOrProcedureReveals Test:T101 Desc:T105	
T571	Datetime 3320 3328	12/10/19
R124	HappensAtOnDuring Arg1:T571 Arg2:T524	
R125	TreatmentDesc Therapy:T524 Desc:T517	
A242	ChronicVal T108 non-chronic
A243	ContinuityVal T108 new
A244	IntentVal T109 TreatmentAssessment
R126	TestOrProcedureReveals Test:T109 Desc:T108	
R127	TreatmentDiscontinuedBecauseOf Therapy:T517 Reason:T108	
T572	Datetime 3423 3431	12/24/19
T573	Datetime 3494 3502	01/07/20
R128	TreatmentDesc Therapy:T526 Desc:T518	
R129	TreatmentDesc Therapy:T517 Desc:T526	
R130	HappensAtOnDuring Arg1:T572 Arg2:T518	
R131	TreatmentDesc Therapy:T525 Desc:T518	
T574	Cycles 3504 3508	C5D1
T575	MedicationRegimen 3509 3515	FOLFOX
A245	TreatmentContinuityVal T575 continuing
A246	TreatmentTypeVal T575 maintenance
A247	TreatmentIntentVal T575 palliative
R132	TreatmentDesc Therapy:T574 Desc:T575	
R133	TreatmentDiscontinuedBecauseOf Therapy:T531 Reason:T108	
R134	TreatmentDesc Therapy:T528 Desc:T517	
R135	HappensAtOnDuring Arg1:T573 Arg2:T575	
R136	TreatmentDesc Therapy:T527 Desc:T519	
T576	Symptom 3658 3676	saltiness in mouth
A248	IsPresentOnFirstCancerDiagnosis T576 no
A249	IsCausedByDiagnosedCancer T576 no
A250	ChronicVal T576 non-chronic
A251	ContinuityVal T576 new
R137	ConditionOrTreatmentCausesProblem Treatment:T519 Prob:T576	
A252	NegationModalityVal T114 negated
A253	NegationModalityVal T519 planned_in_future
A254	IsPresentOnFirstCancerDiagnosis T115 no
A255	IsCausedByDiagnosedCancer T115 no
A256	ChronicVal T115 non-chronic
A257	ContinuityVal T115 stopped
R138	ConditionOrTreatmentCausesProblem Treatment:T575 Prob:T115	
T577	MedicationName 4138 4146	Klor Con
A258	NegationModalityVal T577 hypothetical_in_future
A259	TreatmentTypeVal T577 others
A260	TreatmentIntentVal T577 others
A261	TreatmentCategory T577 Supportive
A262	IsPresentOnFirstCancerDiagnosis T120 no
A263	IsCausedByDiagnosedCancer T120 no
A264	ChronicVal T120 non-chronic
A265	ContinuityVal T120 unclear
A266	NegationModalityVal T121 negated
A267	NegationModalityVal T122 negated
A268	NegationModalityVal T123 negated
A269	NegationModalityVal T124 negated
A270	NegationModalityVal T128 negated
A271	NegationModalityVal T129 negated
A272	NegationModalityVal T130 negated
A273	NegationModalityVal T131 negated
A274	NegationModalityVal T132 negated
A275	NegationModalityVal T133 negated
A276	NegationModalityVal T134 negated
A277	NegationModalityVal T135 negated
A278	NegationModalityVal T136 negated
A279	NegationModalityVal T138 negated
A280	NegationModalityVal T139 negated
A281	NegationModalityVal T140 negated
A282	NegationModalityVal T141 negated
A283	NegationModalityVal T142 negated
A284	NegationModalityVal T143 negated
A285	NegationModalityVal T144 negated
A286	NegationModalityVal T145 negated
A287	NegationModalityVal T146 negated
A288	NegationModalityVal T147 negated
A289	NegationModalityVal T149 negated
A290	NegationModalityVal T150 negated
T578	Symptom 4343 4350	fatigue
A291	IsPresentOnFirstCancerDiagnosis T578 no
A292	IsCausedByDiagnosedCancer T578 no
A293	ChronicVal T578 non-chronic
A294	ContinuityVal T578 improving
T579	Symptom 4362 4380	decreased appetite
A295	IsPresentOnFirstCancerDiagnosis T579 no
A296	IsCausedByDiagnosedCancer T579 no
A297	ChronicVal T579 non-chronic
A298	ContinuityVal T579 improving
T580	Symptom 4396 4407	weight loss
A299	IsPresentOnFirstCancerDiagnosis T580 unclear
A300	IsCausedByDiagnosedCancer T580 unclear
A301	ContinuityVal T580 stable
A302	IsPresentOnFirstCancerDiagnosis T137 no
A303	IsCausedByDiagnosedCancer T137 unclear
A304	ChronicVal T137 non-chronic
A305	ContinuityVal T137 stopped
T3	MedicationName 5070 5102	diphenoxylate-atropine (LOMOTIL)
A306	TreatmentContinuityVal T3 continuing
A307	TreatmentTypeVal T3 others
A308	TreatmentIntentVal T3 others
A309	TreatmentCategory T3 Supportive
A310	TreatmentContinuityVal T157 continuing
A311	TreatmentTypeVal T157 others
A312	TreatmentIntentVal T157 others
A313	TreatmentCategory T157 Supportive
A314	TreatmentContinuityVal T160 continuing
A315	TreatmentTypeVal T160 others
A316	TreatmentIntentVal T160 others
A317	TreatmentCategory T160 Supportive
A318	TreatmentContinuityVal T161 continuing
A319	TreatmentTypeVal T161 others
A320	TreatmentIntentVal T161 others
A321	TreatmentCategory T161 Supportive
A322	TreatmentContinuityVal T163 continuing
A323	TreatmentTypeVal T163 others
A324	TreatmentIntentVal T163 others
A325	TreatmentCategory T163 Supportive
A326	TreatmentContinuityVal T165 continuing
A327	TreatmentTypeVal T165 others
A328	TreatmentIntentVal T165 others
A329	TreatmentCategory T165 Supportive
A330	TreatmentContinuityVal T168 continuing
A331	TreatmentTypeVal T168 others
A332	TreatmentIntentVal T168 others
A333	TreatmentCategory T168 Supportive
A334	TreatmentContinuityVal T169 continuing
A335	TreatmentTypeVal T169 others
A336	TreatmentIntentVal T169 others
A337	TreatmentCategory T169 Supportive
A338	TreatmentContinuityVal T172 continuing
A339	TreatmentTypeVal T172 others
A340	TreatmentIntentVal T172 others
A341	TreatmentCategory T172 Supportive
A342	TreatmentContinuityVal T174 continuing
A343	TreatmentTypeVal T174 others
A344	TreatmentIntentVal T174 others
A345	TreatmentCategory T174 Supportive
A346	TreatmentContinuityVal T177 continuing
A347	TreatmentTypeVal T177 others
A348	TreatmentIntentVal T177 others
A349	TreatmentCategory T177 Supportive
A350	TreatmentContinuityVal T179 continuing
A351	TreatmentTypeVal T179 others
A352	TreatmentIntentVal T179 others
A353	TreatmentCategory T179 Supportive
A354	TreatmentContinuityVal T184 continuing
A355	TreatmentTypeVal T184 others
A356	TreatmentIntentVal T184 others
A357	TreatmentCategory T184 Others
A358	TreatmentContinuityVal T185 continuing
A359	TreatmentTypeVal T185 others
A360	TreatmentIntentVal T185 others
A361	TreatmentCategory T185 Others
A362	TreatmentContinuityVal T183 continuing
A363	TreatmentTypeVal T183 others
A364	TreatmentIntentVal T183 others
A365	TreatmentCategory T183 Others
A366	TreatmentContinuityVal T186 continuing
A367	TreatmentTypeVal T186 others
A368	TreatmentIntentVal T186 others
A369	TreatmentCategory T186 Others
A370	TreatmentContinuityVal T187 continuing
A371	TreatmentTypeVal T187 others
A372	TreatmentIntentVal T187 others
A373	TreatmentCategory T187 Others
A374	TreatmentContinuityVal T188 continuing
A375	TreatmentTypeVal T188 maintenance
A376	TreatmentIntentVal T188 palliative
A377	TreatmentCategory T188 AntiNeoPlastics
A378	TreatmentContinuityVal T194 continuing
A379	TreatmentTypeVal T194 others
A380	TreatmentIntentVal T194 others
A381	TreatmentCategory T194 Supportive
T581	MedicationName 7898 7911	heparin flush
A382	NegationModalityVal T581 affirmed
A383	TreatmentTypeVal T581 others
A384	TreatmentIntentVal T581 others
A385	TreatmentCategory T581 Others
A386	NegationModalityVal T193 affirmed
A387	TreatmentTypeVal T193 others
A388	TreatmentIntentVal T193 others
A389	TreatmentCategory T193 Others
T582	MedicationName 8166 8174	dextrose
A390	NegationModalityVal T582 affirmed
A391	TreatmentTypeVal T582 others
A392	TreatmentIntentVal T582 others
A393	TreatmentCategory T582 Others
A394	NegationModalityVal T189 affirmed
A395	TreatmentTypeVal T189 others
A396	TreatmentIntentVal T189 others
A397	TreatmentCategory T189 Others
A398	TreatmentContinuityVal T196 continuing
A399	TreatmentTypeVal T196 others
A400	TreatmentIntentVal T196 others
A401	TreatmentCategory T196 Supportive
T583	MedicationName 8356 8378	oxaliplatin (ELOXATIN)
A402	TreatmentContinuityVal T583 continuing
A403	TreatmentTypeVal T583 maintenance
A404	TreatmentIntentVal T583 palliative
A405	TreatmentCategory T583 AntiNeoPlastics
T584	TreatmentDosage 5103 5115	2.5-0.025 mg
T585	TreatmentDosage 5296 5308	300 mg total
T586	TreatmentDosage 5517 5521	2 mg
T587	TreatmentDosage 5718 5724	0.5 mg
T588	TreatmentDosage 5877 5881	8 mg
T589	TreatmentDosage 6092 6103	10 mg total
T590	TreatmentDosage 6206 6212	500 mg
T591	TreatmentDosage 6315 6324	2.5-2.5 %
T592	TreatmentDosage 6499 6509	5 mg total
T594	TreatmentDosage 6691 6703	20 mEq total
T593	TreatmentDosage 6959 6970	10-30 mL/hr
T595	TreatmentDosage 7057 7064	90 mcg/
T596	TreatmentDosage 7396 7402	0.3 mg
T597	TreatmentDosage 7481 7489	4,032 mg
A406	NegationModalityVal T156 hypothetical_in_future
T598	Symptom 5625 5633	diarrhea
A407	NegationModalityVal T598 hypothetical_in_future
T599	Symptom 5774 5780	nausea
A408	NegationModalityVal T599 hypothetical_in_future
T600	Symptom 5935 5941	nausea
A409	NegationModalityVal T600 hypothetical_in_future
T601	Symptom 5946 5954	vomiting
A410	NegationModalityVal T601 hypothetical_in_future
T602	Symptom 6145 6151	nausea
A411	NegationModalityVal T602 hypothetical_in_future
T603	Symptom 6156 6164	vomiting
A412	NegationModalityVal T603 hypothetical_in_future
T604	Symptom 6275 6279	Pain
A413	NegationModalityVal T604 hypothetical_in_future
T605	Symptom 6385 6389	pain
A414	NegationModalityVal T605 hypothetical_in_future
A415	NegationModalityVal T178 hypothetical_in_future
A416	NegationModalityVal T162 hypothetical_in_future
R139	TreatmentDesc Therapy:T588 Desc:T165	
R140	TreatmentAdministeredForProblem Treatment:T165 Prob:T600	
R141	TreatmentAdministeredForProblem Treatment:T165 Prob:T601	
R142	TreatmentDesc Therapy:T584 Desc:T3	
R143	TreatmentAdministeredForProblem Treatment:T3 Prob:T156	
T606	MedicationName 5206 5220	EYEBRIGHT ORAL
A417	NegationModalityVal T606 affirmed
A418	TreatmentTypeVal T606 others
A419	TreatmentIntentVal T606 others
R144	TreatmentDesc Therapy:T157 Desc:T585	
T607	MedicationName 5359 5410	glucosam/chond/collagen/hyalur (JOINT SUPPORT ORAL)
A420	TreatmentContinuityVal T607 continuing
A421	TreatmentTypeVal T607 others
A422	TreatmentIntentVal T607 others
A423	TreatmentCategory T607 Others
R145	TreatmentDesc Therapy:T161 Desc:T586	
R146	TreatmentAdministeredForProblem Treatment:T161 Prob:T162	
R147	TreatmentAdministeredForProblem Treatment:T161 Prob:T598	
R148	TreatmentDesc Therapy:T163 Desc:T587	
R149	TreatmentAdministeredForProblem Treatment:T163 Prob:T599	
R150	TreatmentDesc Therapy:T169 Desc:T589	
R151	TreatmentAdministeredForProblem Treatment:T169 Prob:T602	
R152	TreatmentAdministeredForProblem Treatment:T169 Prob:T603	
R153	TreatmentDesc Therapy:T172 Desc:T590	
R154	TreatmentAdministeredForProblem Treatment:T172 Prob:T604	
R155	TreatmentDesc Therapy:T174 Desc:T591	
R156	TreatmentAdministeredForProblem Treatment:T174 Prob:T605	
A424	NegationModalityVal T175 hypothetical_in_future
R157	TreatmentDesc Therapy:T177 Desc:T592	
R158	TreatmentAdministeredForProblem Treatment:T177 Prob:T178	
R159	TreatmentDesc Therapy:T179 Desc:T594	
R160	TreatmentDesc Therapy:T183 Desc:T593	
T608	TreatmentDosage 7314 7319	50 mg
R161	TreatmentDesc Therapy:T186 Desc:T608	
R162	TreatmentDesc Therapy:T187 Desc:T596	
R163	TreatmentDesc Therapy:T188 Desc:T597	
A425	TreatmentTypeVal T190 others
A426	TreatmentIntentVal T190 others
A427	TreatmentCategory T190 Others
T609	TreatmentDosage 7696 7705	300 Units
R164	TreatmentDesc Therapy:T190 Desc:T609	
T610	TreatmentDosage 7942 7951	500 Units
R165	TreatmentDesc Therapy:T581 Desc:T610	
T611	TreatmentDosage 8071 8077	100 mg
T612	TreatmentDosage 8156 8162	672 mg
R166	TreatmentDesc Therapy:T193 Desc:T611	
R167	TreatmentDesc Therapy:T194 Desc:T612	
T613	TreatmentDosage 8178 8184	308 mL
R168	TreatmentDesc Therapy:T582 Desc:T613	
T614	TreatmentDosage 8313 8317	1 mg
R169	TreatmentDesc Therapy:T196 Desc:T614	
T615	TreatmentDosage 8379 8387	142.8 mg
T616	TreatmentDosage 8403 8409	579 mL
R170	TreatmentDesc Therapy:T583 Desc:T615	
R171	TreatmentDesc Therapy:T616 Desc:T198	
T617	SectionSkip 11066 11432	Date Value Ref Range Status   01/07/2020 8,274 (H) <38 U/mL Final     Comment:     Performed using the ***** Architect Chemiluminescent Microparticle Immunoassay (*****).     Carcinoembryonic Antigen   Date Value Ref Range Status   12/10/2019 4.2 <5.1 ug/L Final     Comment:     Performed using the ***** Architect Chemiluminescent Microparticle Immunoassay (*****)
A428	SectionSkipType T617 laboratory
T618	SectionSkip 11442 11664;11667 13623;13626 15553;15556 15717	Imaging Results:    I personally reviewed and interpreted the patient's relevant imaging studies in conjunction with the corresponding formal radiology reports, as follows:  Ct Abdomen /pelvis With Contrast    Result Date: 12/10/2019  CT ABDOMEN/PELVIS WITH CONTRAST  *****/*****/***** 8:35 AM CLINICAL HISTORY: Restaging scans. Pancreatic cancer COMPARISON:  CT abdomen/pelvis from 09/24/2019. TECHNIQUE: Following the administration of 150 cc of Omnipaque 350, contiguous 1.25-mm collimation axial images were obtained through the abdomen and pelvis. Coronal and sagittal reformats were also obtained. CONTRAST MEDIA: Intravenous and oral iodinated contrasts were administered. FINDINGS: Visualized lung bases:  For chest findings, please see the separately dictated report from the CT of the chest of the same date. Liver:  Diffuse hepatic steatosis. Heterogeneous and diminished enhancement. Mild intrahepatic biliary ductal dilatation. Gallbladder: Unremarkable Spleen:  Unremarkable Pancreas:  4.4 x 3.5 cm mass in pancreatic body (series 5, image 48), with upstream pancreatic ductal dilatation and parenchymal atrophy, similar to prior study from 09/24/2019. Adrenal Glands:  Unremarkable Kidneys:  Unremarkable GI Tract: Small hiatal hernia. Diffuse wall edema involving the ascending and transverse colon. No obstruction. Vasculature:  Encasement and obstruction of the portal confluence by the pancreatic mass, with further attenuation of right and left portal veins. Encasement of celiac axis and superior mesenteric artery, with severe stenosis of hepatic artery, splenic artery, as well as superior mesenteric artery. Lymphadenopathy: Several periportal/peripancreatic lymph nodes measuring up to 1 cm, grossly similar to prior study. Peritoneum: Mild edema and trace ascites in upper abdomen. Bladder: Unremarkable Reproductive organs: Unremarkable Bones:  Multilevel degenerative changes in thoracic and lumbar spine, with grade 1 anterolisthesis of L3 on L4 and L4 on L5. Extraperitoneal soft tissues: Substantial interval weight loss. Lines/drains/medical devices: None RADIATION DOSE INDICATORS: Exposure Events: 4 , CTDIvol Min: 12 mGy, CTDIvol Max: 13.4 mGy, DLP: 1012.8 mGy.cm. The following accession numbers are related to this dose report *****,*****     1. Pancreatic mass as detailed above, with encasement and severe narrowing of celiac and superior mesenteric arteries. 2. Ascending and transverse colitis. Report dictated by: ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging    Ct Chest With Contrast    Result Date: 12/10/2019  CT CHEST WITH CONTRAST CLINICAL HISTORY:  Cancer metastatic to lung suspected No iodinated contrast contraindication Scan request unrelated to lung cancer Restaging scans. COMPARISON: 09/24/2019 TECHNIQUE: Serial 1.25 mm axial images through the chest were obtained after the administration of intravenous contrast. RADIATION DOSE INDICATORS: Exposure Events: 4 , CTDIvol Min: 12 mGy, CTDIvol Max: 13.4 mGy, DLP: 1012.8 mGy.cm. The following accession numbers are related to this dose report *****,***** FINDINGS: LUNGS: Unchanged right upper lobe mixed solid groundglass nodule measuring 1.0 x 0.5 cm (series 14 image 56). Unchanged nodular scar or atelectasis adjacent to the osteophyte in the medial right lower lobe. No new nodules. PLEURA: The pleura is normal. MEDIASTINUM: No intrathoracic lymphadenopathy by CT size criteria. Heterogeneous appearance of the right thyroid gland is unchanged. HEART/GREAT VESSELS: New right chest port with tip in the lower right atrium. Unchanged mild flattening of the ventricular septum which may be due to increased right heart pressures. BONES/SOFT TISSUES: No suspicious bone or soft tissue lesions in the chest. VISIBLE ABDOMEN: Please refer to CT of the abdomen and pelvis reported separately for intra-abdominal findings.     1. No significant interval change in right upper lobe mixed solid and groundglass nodule measuring 1.0 x 0.5 cm. This may reflect scarring, primary lung neoplasm (specifically pulmonary adenocarcinoma), or metastatic disease. Continued surveillance is recommended. Report dictated by: ***** ***** *****, MD, signed by: ***** ***** *****, MD Department of Radiology and Biomedical Imaging
T619	SectionSkip 15899 16247	COMMENTS:   The aspirate material shows invasive ductal carcinoma of the pancreas.  Immunohistochemistry was performed to evaluate the status of DNA  mismatch repair protein expression on block A1. The results in the tumor  cell nuclei are:  MLH1 expression: Present.   PMS2 expression: Present.  MSH2 expression: Present.  MSH6 expression: Present
A430	SectionSkipType T619 pathology_report
T620	Age 16312 16314	73
T621	ClinicalCondition 16349 16353	PDAC
A431	ChronicVal T621 non-chronic
A432	ContinuityVal T621 stable
T622	LocalInvasion 16332 16348	locally advanced
A433	EpisodeDescription T622 FirstOccurrence
R172	TumorDesc TumorDetails:T622 Desc:T621	
A434	TreatmentContinuityVal T361 continuing
A435	TreatmentTypeVal T361 maintenance
A436	TreatmentIntentVal T361 palliative
R173	TreatmentAdministeredForProblem Treatment:T361 Prob:T621	
T623	Cycles 16371 16372	1
T624	Datetime 16373 16381	10/22/19
R174	HappensAtOnDuring Arg1:T624 Arg2:T623	
R175	HappensAtOnDuring Arg1:T624 Arg2:T361	
T625	Duration 16436 16446	4-6 months
T626	Frequency 16476 16480	q2mo
A437	TreatmentContinuityVal T362 continuing
A438	TreatmentTypeVal T362 maintenance
A439	TreatmentIntentVal T362 palliative
R176	Temporal Arg1:T625 Arg2:T362	
T627	Radiology 16481 16486	scans
A440	NegationModalityVal T627 planned_in_future
A441	IntentVal T627 TreatmentAssessment
R177	Temporal Arg1:T626 Arg2:T627	
A442	TreatmentContinuityVal T364 continuing
A443	TreatmentTypeVal T364 maintenance
A444	TreatmentIntentVal T364 palliative
T628	ProcedureName 16585 16603	surgical prospects
A445	NegationModalityVal T628 hypothetical_in_future
A446	IntentVal T628 treatment-curative
A447	TreatmentTypeVal T628 local
A448	TreatmentCategory T628 AntiNeoPlastics
A449	NegationModalityVal T366 hypothetical_in_future
R178	ProcedureDesc Procedure:T628 Desc:T366	
A450	NegationModalityVal T367 hypothetical_in_future
A451	TreatmentTypeVal T367 local
A452	TreatmentIntentVal T367 palliative
A453	NegationModalityVal T368 hypothetical_in_future
A454	TreatmentTypeVal T368 local
A455	TreatmentIntentVal T368 palliative
A456	NegationModalityVal T371 hypothetical_in_future
A457	TreatmentTypeVal T371 local
A458	TreatmentIntentVal T371 palliative
A459	TreatmentTypeVal T369 local
A460	TreatmentIntentVal T369 palliative
A461	TreatmentCategory T369 AntiNeoPlastics
A462	NegationModalityVal T372 hypothetical_in_future
A463	IntentVal T372 treatment-curative
A464	TreatmentTypeVal T372 local
A465	TreatmentCategory T372 AntiNeoPlastics
T629	MedicationRegimen 16930 16940	FOLFIRINOX
A466	TreatmentContinuityVal T629 continuing
A467	TreatmentTypeVal T629 maintenance
A468	TreatmentIntentVal T629 palliative
T630	MedicationRegimen 17046 17057	mFOLFIRINOX
A469	TreatmentContinuityVal T630 continuing
A470	TreatmentTypeVal T630 maintenance
A471	TreatmentIntentVal T630 palliative
T631	MedicationRegimen 17857 17863	FOLFOX
A472	TreatmentContinuityVal T631 continuing
A473	TreatmentTypeVal T631 maintenance
A474	TreatmentIntentVal T631 palliative
T632	Cycles 17041 17042	1
R179	TreatmentDesc Therapy:T632 Desc:T630	
A475	ChronicVal T374 non-chronic
A476	ContinuityVal T374 unclear
A477	ChronicVal T376 non-chronic
A478	ContinuityVal T376 unclear
A479	ChronicVal T378 non-chronic
A480	ContinuityVal T378 unclear
A481	ChronicVal T377 non-chronic
A482	ContinuityVal T377 unclear
A483	ChronicVal T375 non-chronic
A484	ContinuityVal T375 unclear
T633	MedicationName 17177 17180	IVF
A485	TreatmentContinuityVal T633 finished
A486	TreatmentTypeVal T633 others
A487	TreatmentIntentVal T633 others
A488	TreatmentCategory T633 Supportive
T634	MedicationName 17207 17219	IV potassium
A489	TreatmentContinuityVal T634 finished
A490	TreatmentTypeVal T634 others
A491	TreatmentIntentVal T634 others
A492	TreatmentCategory T634 Supportive
T635	SectionSkip 4980 5853;5856 7774;7777 8502	Current Medications:  Current Outpatient Medications   Medication Sig Dispense Refill    diphenoxylate-atropine (LOMOTIL) 2.5-0.025 mg tablet Take 1 tablet by mouth 4 (four) times daily as needed for Diarrhea 60 tablet 1    EYEBRIGHT ORAL Take by mouth.      gabapentin (NEURONTIN) 300 mg capsule Take 1 capsule (300 mg total) by mouth 3 (three) times daily. 90 capsule 5    glucosam/chond/collagen/hyalur (JOINT SUPPORT ORAL) Take by mouth.      Lactobacillus acidophilus (PROBIOTIC ORAL) Take by mouth.      loperamide (IMODIUM) 2 mg capsule Take two capsules by mouth at the onset of diarrhea, then take one capsule every 2 hours until diarrhea-free for 12 hours. 30 capsule 5    LORazepam (ATIVAN) 0.5 mg tablet Take 1 tablet (0.5 mg total) by mouth every 8 (eight) hours as needed (nausea) 30 tablet 3    multivitamin tablet Take 1 tablet by mouth daily.      ondansetron (ZOFRAN) 8 mg tablet Take 1 tablet three times a day as needed for nausea and vomiting. Start 2 days after last dose of palonosetron (Aloxi) is given. 30 tablet 5    prochlorperazine (COMPAZINE) 10 mg tablet Take 1 tablet (10 mg total) by mouth every 6 (six) hours as needed (nausea and vomiting) 30 tablet 5    acetaminophen (TYLENOL) 500 mg tablet Take 500 mg by mouth every 6 (six) hours as needed for Pain.      lidocaine-prilocaine (EMLA) 2.5-2.5 % cream Apply cream one hour before port access as needed for pain. (Patient not taking: Reported on 10/22/2019  ) 30 g 2    oxyCODONE (ROXICODONE) 5 mg tablet Take 1 tablet (5 mg total) by mouth every 8 (eight) hours as needed for Pain. (Patient not taking: Reported on 10/01/2019  ) 20 tablet 0    potassium chloride (KLOR-CON 10) 10 mEq ER tablet Take 2 tablets (20 mEq total) by mouth daily 60 tablet 3     No current facility-administered medications for this visit.      Facility-Administered Medications Ordered in Other Visits   Medication Dose Route Frequency Provider Last Rate Last Dose    0.9 % sodium chloride infusion  10-30 mL/hr Intravenous Continuous ***** *****, MD        albuterol (PROVENTIL HFA;VENTOLIN HFA) 90 mcg/actuation inhaler 2 puff  2 puff Inhalation Once PRN ***** *****, MD        dextrose 5% infusion  10-30 mL/hr Intravenous Continuous ***** *****, MD 30 mL/hr at 01/21/20 1220 30 mL/hr at 01/21/20 1220    diphenhydrAMINE (BENADRYL) injection 50 mg  50 mg Intravenous Once PRN ***** *****, MD        EPINEPHrine (EPIPEN) injection 0.3 mg  0.3 mg Intramuscular Once PRN ***** *****, MD        fluorouraciL (ADRUCIL) 4,032 mg in sodium chloride 0.9 % 92 mL chemo infusion - for home use  2,400 mg/m2 (Treatment Plan Recorded) Intravenous Once Q46H (Pump) ***** ***** *****, *****        heparin flush 100 unit/mL injection syringe 300 Units  300 Units Intravenous PRN ***** *****, MD        heparin flush 100 unit/mL injection syringe 500 Units  500 Units Intravenous PRN ***** ***** *****, *****   500 Units at 01/21/20 0941    heparin flush 100 unit/mL injection syringe 500 Units  500 Units Intravenous PRN ***** *****, MD        hydrocortisone sodium succinate (SOLU-CORTEF) 100 mg/2 mL injection 100 mg  100 mg Intravenous Once PRN ***** *****, MD        leucovorin (WELLCOVORIN) 672 mg in dextrose 5% 308 mL infusion  400 mg/m2 (Treatment Plan Recorded) Intravenous Once ***** ***** *****, *****        LORazepam (ATIVAN) tablet 1 mg  1 mg Oral Once PRN ***** *****, MD        oxaliplatin (ELOXATIN) 142.8 mg in dextrose 5% 579 mL chemo infusion  85 mg/m2 (Treatment Plan Recorded) Intravenous Once ***** ***** *****, *****
A493	TreatmentContinuityVal T635 finished
A494	TreatmentTypeVal T635 others
A495	TreatmentIntentVal T635 others
A496	TreatmentCategory T635 Supportive
A429	TreatmentContinuityVal T618 finished
A497	TreatmentTypeVal T618 others
A498	TreatmentIntentVal T618 others
A499	TreatmentCategory T618 Supportive
A500	SectionSkipType T618 radiology_report
A501	SectionSkipType T635 medications
R180	TreatmentAdministeredForProblem Treatment:T633 Prob:T377	
R181	TreatmentAdministeredForProblem Treatment:T634 Prob:T378	
A502	TreatmentContinuityVal T381 discontinued_early
A503	TreatmentTypeVal T381 maintenance
A504	TreatmentIntentVal T381 palliative
A505	TreatmentCategory T381 AntiNeoPlastics
T636	TreatmentDosage 17256 17264	120mg/m2
R182	TreatmentDesc Therapy:T381 Desc:T636	
T637	TreatmentDoseModification 17229 17241	dose reduced
R183	TreatmentDesc Therapy:T637 Desc:T381	
T638	Cycles 17278 17279	2
R184	TreatmentDesc Therapy:T638 Desc:T381	
T639	Datetime 17283 17291	11/19/19
A506	TreatmentContinuityVal T383 continuing
A507	TreatmentTypeVal T383 others
A508	TreatmentCategory T383 Supportive
R185	BeginsOnOrAt Arg1:T639 Arg2:T383	
R186	TreatmentAdministeredForProblem Treatment:T383 Prob:T376	
A509	ChronicVal T385 non-chronic
A510	ContinuityVal T385 unclear
A511	ChronicVal T386 non-chronic
A512	ContinuityVal T386 unclear
A513	ChronicVal T387 non-chronic
A514	ContinuityVal T387 unclear
T640	Cycles 17460 17461	3
R187	TreatmentDesc Therapy:T630 Desc:T640	
T641	Duration 17477 17483	1 week
R188	HappensAfter Arg1:T641 Arg2:T640	
T642	Datetime 17491 17502	December 03
R189	HappensAfter Arg1:T642 Arg2:T640	
T643	DiagnosticLabTest 17547 17554	CA 19-9
A515	IntentVal T643 TreatmentAssessment
T644	LabTestResult 17563 17566	11K
A516	LabTestResultVal T644 abnormal
T645	LabTestResult 17556 17560	5000
A517	LabTestResultVal T645 abnormal
R190	ResultOfTest Desc:T645 Test:T643	
R191	ResultOfTest Desc:T644 Test:T643	
T646	DiseaseState 17556 17566	5000-->11K
A518	NegationModalityVal T646 uncertain_in_present
A519	DiseaseStateVal T646 progression-others
A520	IntentVal T390 TreatmentAssessment
T647	Datetime 17604 17612	12/10/19
R192	HappensAtOnDuring Arg1:T390 Arg2:T647	
T648	DiseaseState 17637 17651	stable disease
A521	DiseaseStateVal T648 stability
R193	TestOrProcedureReveals Test:T390 Desc:T648	
T649	Metastasis 17680 17690	metastases
A522	NegationModalityVal T649 negated
R194	TestOrProcedureReveals Test:T390 Desc:T649	
A523	ChronicVal T393 non-chronic
A524	ContinuityVal T393 new
R195	TestOrProcedureReveals Test:T390 Desc:T393	
T650	Symptom 17750 17758	diarrhea
A525	IsPresentOnFirstCancerDiagnosis T650 no
A526	IsCausedByDiagnosedCancer T650 no
A527	ChronicVal T650 non-chronic
A528	ContinuityVal T650 improving
R196	ConditionOrTreatmentCausesProblem Treatment:T393 Prob:T650	
R197	TreatmentDiscontinuedBecauseOf Therapy:T381 Reason:T393	
T651	Cycles 17930 17934	C6D1
R198	TreatmentDesc Therapy:T631 Desc:T651	
T652	ClinicalCondition 17905 17909	PDAC
A529	ChronicVal T652 chronic
A530	ContinuityVal T652 stable
T653	LocalInvasion 17888 17904	Locally Advanced
A531	EpisodeDescription T653 FirstOccurrence
R199	TumorDesc TumorDetails:T653 Desc:T652	
T654	Datetime 17953 17961	01/21/20
T655	MedicationName 17971 17981	irinotecan
A532	TreatmentContinuityVal T655 discontinued_early
A533	TreatmentTypeVal T655 maintenance
A534	TreatmentIntentVal T655 palliative
A535	TreatmentCategory T655 AntiNeoPlastics
T656	Cycles 17989 17990	3
R200	TreatmentDesc Therapy:T656 Desc:T655	
T657	ClinicalCondition 17999 18006	colitis
A536	ChronicVal T657 non-chronic
A537	ContinuityVal T657 unclear
R201	TreatmentDiscontinuedBecauseOf Therapy:T655 Reason:T657	
A538	IntentVal T402 TreatmentAssessment
R202	TestOrProcedureReveals Test:T402 Desc:T657	
T658	PerformanceStatus 18017 18035	performance status
A539	PerformanceStatusType T658 Other
A540	TreatmentContinuityVal T403 continuing
A541	TreatmentTypeVal T403 maintenance
A542	TreatmentIntentVal T403 palliative
A543	TreatmentContinuityVal T404 continuing
A544	TreatmentTypeVal T404 maintenance
A545	TreatmentIntentVal T404 palliative
A546	TreatmentCategory T404 AntiNeoPlastics
A547	TreatmentContinuityVal T405 continuing
A548	TreatmentTypeVal T405 maintenance
A549	TreatmentIntentVal T405 palliative
A550	TreatmentCategory T405 AntiNeoPlastics
T659	TreatmentDosage 18100 18107	85mg/m2
E1	TreatmentDosage:T659 
T660	TreatmentDosage 18113 18122	2400mg/m2
E2	TreatmentDosage:T660 
A551	TreatmentContinuityVal T406 continuing
A552	TreatmentTypeVal T406 others
A553	TreatmentIntentVal T406 others
A554	TreatmentCategory T406 Supportive
A555	TreatmentContinuityVal T407 continuing
A556	TreatmentTypeVal T407 others
A557	TreatmentIntentVal T407 others
A558	TreatmentCategory T407 Supportive
A559	TreatmentContinuityVal T408 continuing
A560	TreatmentTypeVal T408 others
A561	TreatmentIntentVal T408 others
A562	TreatmentCategory T408 Supportive
T661	MedicationName 18189 18195	ativan
A563	TreatmentContinuityVal T661 continuing
A564	TreatmentTypeVal T661 others
A565	TreatmentIntentVal T661 others
A566	TreatmentCategory T661 Supportive
T662	MedicationName 18205 18207	NS
A567	TreatmentContinuityVal T662 continuing
A568	TreatmentTypeVal T662 others
A569	TreatmentIntentVal T662 others
A570	TreatmentCategory T662 Supportive
T663	MedicationName 18214 18230	PO dexamethasone
A571	TreatmentContinuityVal T663 continuing
A572	TreatmentTypeVal T663 others
A573	TreatmentIntentVal T663 others
A574	TreatmentCategory T663 Supportive
A575	TreatmentContinuityVal T413 continuing
A576	TreatmentTypeVal T413 others
A577	TreatmentIntentVal T413 others
A578	TreatmentCategory T413 Supportive
A579	TreatmentContinuityVal T414 continuing
A580	TreatmentTypeVal T414 others
A581	TreatmentIntentVal T414 others
A582	TreatmentCategory T414 Supportive
T664	MedicationName 18267 18275	Fulphila
A583	TreatmentContinuityVal T664 continuing
A584	TreatmentTypeVal T664 others
A585	TreatmentIntentVal T664 others
A586	TreatmentCategory T664 Supportive
A587	TreatmentContinuityVal T409 continuing
A588	TreatmentTypeVal T409 others
A589	TreatmentIntentVal T409 others
T665	Frequency 18185 18188	prn
R203	Temporal Arg1:T665 Arg2:T661	
T666	TreatmentDosage 18202 18204	1L
R204	TreatmentDesc Therapy:T666 Desc:T662	
T667	TreatmentDosage 18209 18213	12mg
R205	TreatmentDesc Therapy:T667 Desc:T663	
T668	Frequency 18232 18235	prn
A590	NegationModalityVal T664 negated
T669	DiagnosticLabTest 18313 18320	CA 19-9
A591	IntentVal T669 TreatmentAssessment
A592	ContinuityVal T419 unclear
T670	Cycles 18401 18402	8
T671	DiagnosticLabTest 18412 18419	CA 19-9
A593	IntentVal T671 TreatmentAssessment
A594	NegationModalityVal T420 planned_in_future
T672	Frequency 18404 18411	monthly
R206	Temporal Arg1:T672 Arg2:T671	
A595	IsCausedByDiagnosedCancer T421 no
A596	ChronicVal T421 non-chronic
A597	ContinuityVal T421 stopped
T673	Datetime 18506 18514	12/10/19
T674	ClinicalCondition 18532 18539	colitis
A598	ChronicVal T674 non-chronic
A599	ContinuityVal T674 unclear
R207	HappensAtOnDuring Arg1:T673 Arg2:T674	
A600	IntentVal T422 TreatmentAssessment
R208	HappensAtOnDuring Arg1:T422 Arg2:T673	
T675	MedicationName 18554 18564	irinotecan
A601	TreatmentContinuityVal T675 discontinued_early
A602	TreatmentTypeVal T675 maintenance
A603	TreatmentIntentVal T675 palliative
A604	TreatmentCategory T675 AntiNeoPlastics
T676	Datetime 18570 18572	C3
R209	EndsOnOrAt Arg1:T676 Arg2:T675	
A605	TreatmentIntentVal T425 others
A606	TreatmentCategory T425 Supportive
T677	Frequency 18643 18646	prn
R210	Temporal Arg1:T677 Arg2:T425	
A607	ChronicVal T426 non-chronic
A608	ContinuityVal T426 stable
A609	TreatmentContinuityVal T427 planned
A610	TreatmentTypeVal T427 others
A611	TreatmentIntentVal T427 others
A612	TreatmentCategory T427 Supportive
T678	MedicationName 18724 18732	40mEq PO
A613	TreatmentContinuityVal T678 planned
A614	TreatmentTypeVal T678 others
A615	TreatmentIntentVal T678 others
A616	TreatmentCategory T678 Supportive
T679	MedicationName 18742 18750	Klor Con
A617	TreatmentContinuityVal T679 planned
A618	TreatmentTypeVal T679 others
A619	TreatmentIntentVal T679 others
A620	TreatmentCategory T679 Supportive
T680	Frequency 18739 18741	4x
T681	TreatmentDosage 18751 18757	10 mEq
R211	TreatmentDesc Therapy:T681 Desc:T679	
R212	Temporal Arg1:T680 Arg2:T679	
A621	TreatmentContinuityVal T431 planned
A622	TreatmentTypeVal T431 others
A623	TreatmentIntentVal T431 others
A624	TreatmentCategory T431 Supportive
T682	MedicationName 18836 18844	Klor Con
T683	TreatmentDosage 18845 18851	10 mEq
A625	TreatmentContinuityVal T682 planned
A626	TreatmentTypeVal T682 others
A627	TreatmentIntentVal T682 others
A628	TreatmentCategory T682 Supportive
T684	MedicationName 18940 18948	Klor Con
A629	TreatmentContinuityVal T684 planned
A630	TreatmentTypeVal T684 others
A631	TreatmentIntentVal T684 others
A632	TreatmentCategory T684 Supportive
A633	NegationModalityVal T684 hypothetical_in_future
T685	TreatmentDosage 18993 18999	20 mEq
R213	TreatmentDesc Therapy:T684 Desc:T685	
A634	NegationModalityVal T435 hypothetical_in_future
A635	ChronicVal T436 non-chronic
A636	ContinuityVal T436 stable
T686	MedicationName 19188 19196	liquid K
A637	TreatmentCategory T686 Supportive
T687	MedicationName 19201 19207	MicroK
A638	TreatmentCategory T687 Supportive
A639	TreatmentContinuityVal T686 finished
A640	TreatmentContinuityVal T687 finished
A641	ChronicVal T438 non-chronic
A642	ContinuityVal T438 stable
A643	ChronicVal T439 non-chronic
A644	ContinuityVal T439 stable
T688	Radiology 19435 19445;19448 19457	diagnostic mammogram
A645	IntentVal T688 diagnosis
A646	IntentVal T441 diagnosis
A647	NegationModalityVal T688 planned_in_future
A648	NegationModalityVal T441 planned_in_future
T689	Datetime 19484 19492	11/26/19
A649	GenomicTestType T442 Germline
T690	GenomicTestResult 19560 19593	VUS in RECQL4 c.*****>G (p.*****)
A650	GenomicTestType T690 Germline
R214	ResultOfTest Desc:T690 Test:T442	
T691	Frequency 18833 18835	4x
R215	Temporal Arg1:T691 Arg2:T682	
T692	Datetime 17061 17069	10/22/19
R216	BeginsOnOrAt Arg1:T692 Arg2:T630	
R217	HappensAtOnDuring Arg1:T632 Arg2:T692	
T693	RadPathResult 16965 17020	excellent(sometimes near-complete) pathologic responses
A651	NegationModalityVal T693 hypothetical_in_future
A652	RadPathResultVal T693 TreatmentResponse
R218	HappensAtOnDuring Arg1:T639 Arg2:T638	
R219	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T374	
R220	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T375	
R221	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T376	
R222	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T377	
R223	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T378	
R224	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T385	
R225	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T386	
R226	ConditionOrTreatmentCausesProblem Treatment:T630 Prob:T387	
T694	TreatmentType 17935 17944	treatment
A653	TreatmentContinuityVal T694 continuing
A654	TreatmentTypeVal T694 maintenance
A655	TreatmentIntentVal T694 palliative
R227	HappensAtOnDuring Arg1:T654 Arg2:T651	
R228	TreatmentDesc Therapy:E1 Desc:T404	
R229	TreatmentDesc Therapy:E2 Desc:T405	
T695	Duration 18128 18131	46h
R230	HappensAtOnDuring Arg1:T695 Arg2:T405	
T696	Frequency 18185 18188	prn
R231	Temporal Arg1:T696 Arg2:T661	
R232	Temporal Arg1:T668 Arg2:T413	
R233	Temporal Arg1:T668 Arg2:T414	
R234	HappensAtOnDuring Arg1:T415 Arg2:T414	
T697	Datetime 18264 18266	D3
R235	HappensAtOnDuring Arg1:T697 Arg2:T664	
T698	Datetime 18768 18770	D1
T699	Datetime 18776 18778	D3
R236	HappensAtOnDuring Arg1:T698 Arg2:T679	
R237	HappensAtOnDuring Arg1:T698 Arg2:T678	
R238	HappensAtOnDuring Arg1:T698 Arg2:T427	
R239	HappensAtOnDuring Arg1:T699 Arg2:T431	
R240	HappensAtOnDuring Arg1:T699 Arg2:T682	
T700	TreatmentDosage 18909 18911	1g
T701	MedicationName 18891 18893	Mg
A656	TreatmentContinuityVal T701 planned
A657	TreatmentTypeVal T701 others
A658	TreatmentIntentVal T701 others
A659	TreatmentCategory T701 Supportive
R241	TreatmentDesc Therapy:T700 Desc:T701	
T702	Frequency 19000 19005	daily
R242	Temporal Arg1:T702 Arg2:T684	
T703	Site 19408 19414	breast
T704	Laterality 19406 19407	R
R243	LateralityOfSite Arg1:T704 Arg2:T703	
R244	SiteOf Arg1:T703 Arg2:T439	
R245	TestOrProcedureConductedForProblem Test:T688 Prob:T439	
R246	TestOrProcedureConductedForProblem Test:T441 Prob:T439	
R247	HappensAfter Arg1:T689 Arg2:T441	
R70	SizeOf Arg1:T452 Arg2:T453	
T705	ap_start 16252 16262	Impression
T706	ap_end 19696 19698	2w
T707	hpi_end 4257 4267	neuropathy
T708	hpi_start 19 21	Ms
R248	HappensAtOnDuring Arg1:T520 Arg2:T512	
R249	BeginsOnOrAt Arg1:T512 Arg2:T56	
R250	BeginsOnOrAt Arg1:T512 Arg2:T57	
R251	BeginsOnOrAt Arg1:T512 Arg2:T57	
R252	BeginsOnOrAt Arg1:T512 Arg2:T58	
R253	BeginsOnOrAt Arg1:T541 Arg2:T65	
R254	BeginsOnOrAt Arg1:T541 Arg2:T66	
R255	BeginsOnOrAt Arg1:T558 Arg2:T547	
R256	BeginsOnOrAt Arg1:T558 Arg2:T75	
R257	BeginsOnOrAt Arg1:T558 Arg2:T548	
R258	EndsOnOrAt Arg1:T558 Arg2:T547	
R259	EndsOnOrAt Arg1:T558 Arg2:T75	
R260	EndsOnOrAt Arg1:T558 Arg2:T548	
R261	BeginsOnOrAt Arg1:T558 Arg2:T559	
R262	BeginsOnOrAt Arg1:T557 Arg2:T550	
R263	EndsOnOrAt Arg1:T557 Arg2:T550	
R264	BeginsOnOrAt Arg1:T557 Arg2:T549	
R265	EndsOnOrAt Arg1:T557 Arg2:T549	
R266	BeginsOnOrAt Arg1:T557 Arg2:T560	
R267	EndsOnOrAt Arg1:T557 Arg2:T560	
R268	HappensAtOnDuring Arg1:T557 Arg2:T560	
R269	EndsOnOrAt Arg1:T571 Arg2:T529	
R270	BeginsOnOrAt Arg1:T692 Arg2:T633	
R271	EndsOnOrAt Arg1:T692 Arg2:T633	
R272	HappensAtOnDuring Arg1:T692 Arg2:T633	
R273	BeginsOnOrAt Arg1:T692 Arg2:T634	
R274	EndsOnOrAt Arg1:T692 Arg2:T634	
R275	HappensAtOnDuring Arg1:T692 Arg2:T634	
